

# ASPIRIN TO TARGET ARTERIAL EVENTS IN CHRONIC KIDNEY DISEASE (ATTACK)

Final Version 4.0  
24 September 2021

<b>Short title:</b>	Aspirin in Chronic Kidney Disease
<b>Acronym:</b>	ATTACK
<b>EudraCT number:</b>	2018-000644-26
<b>Trial Registration:</b>	NCT03796156
<b>ISRCTN:</b>	ISRCTN40920200
<b>CTA reference:</b>	16730/0223/001-0001
<b>IRAS Project ID:</b>	228831
<b>Trial Sponsor:</b>	University of Southampton
<b>Sponsor reference:</b>	31844
<b>Funding Source:</b>	National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme (Ref: 16/31/127)  British Heart Foundation (Ref: SP/17/14/33355)

## TRIAL PERSONNEL AND CONTACT DETAILS

<b>CHIEF INVESTIGATORS</b>	
Professor Hugh Gallagher	Consultant Nephrologist Epsom and St Helier University Hospitals NHS Trust Visiting Professor University of Southampton <a href="mailto:hugh.gallagher1@nhs.net">hugh.gallagher1@nhs.net</a>
Professor Paul Roderick	Professor of Public Health Primary Care & Population Sciences Academic Units University of Southampton <a href="mailto:pjr@soton.ac.uk">pjr@soton.ac.uk</a>
Dr Simon Fraser	Associate Professor of Public Health Primary Care & Population Sciences Academic Units University of Southampton <a href="mailto:s.fraser@soton.ac.uk">s.fraser@soton.ac.uk</a>
<b>PRINCIPAL INVESTIGATORS</b>	
<u>Northern Hub</u> Professor Ahmet Fuat	Honorary Chair in Primary Care Cardiology School of Health, Medicine and Pharmacy University of Durham / Carmel Medical Practice <a href="mailto:ahmetfuat@nhs.net">ahmetfuat@nhs.net</a>
<u>Midlands Hub</u> Professor David Fitzmaurice / Professor Hugh Gallagher	Professor of Cardiorespiratory Primary Care Warwick Clinical Trials Unit Warwick Medical School <a href="mailto:d.fitzmaurice@warwick.ac.uk">d.fitzmaurice@warwick.ac.uk</a> / <a href="mailto:hugh.gallagher1@nhs.net">hugh.gallagher1@nhs.net</a>
<u>Southern Hub</u> Professor Michael Moore / Dr Mark Lown	Director of Primary Care & Population Sciences Academic Units University of Southampton <a href="mailto:mvm198@soton.ac.uk">mvm198@soton.ac.uk</a> / <a href="mailto:m.lown@soton.ac.uk">m.lown@soton.ac.uk</a>

<b>CO-INVESTIGATORS</b>	
Dr Kathryn Griffith	Retired General Practitioner <a href="mailto:kathryn.e.griffith@me.com">kathryn.e.griffith@me.com</a>
Professor Chris Hawkey	Professor of Gastroenterology Nottingham Digestive Diseases Centre University of Nottingham <a href="mailto:cj.hawkey@nottingham.ac.uk">cj.hawkey@nottingham.ac.uk</a>
Dr Robert Henderson	Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals NHS Trust <a href="mailto:Robert.Henderson@nuh.nhs.uk">Robert.Henderson@nuh.nhs.uk</a>
Professor Joanne Lord	Director of Health Technology Assessments Centre University of Southampton <a href="mailto:J.Lord@soton.ac.uk">J.Lord@soton.ac.uk</a>
Dr Paul Stevens	Consultant Nephrologist East Kent Hospitals NHS Foundation Trust <a href="mailto:pstevens@nhs.net">pstevens@nhs.net</a>
Professor Maarten Taal	Professor of Medicine and Consultant Nephrologist Faculty of Medicine and Health Sciences University of Nottingham <a href="mailto:maarten.taal1@nhs.net">maarten.taal1@nhs.net</a>
<b>CO-APPLICANTS - PATIENT AND PUBLIC INVOLVEMENT</b>	
Ms Fiona Loud	Policy Director Kidney Care UK <a href="mailto:fiona.loud@kidneycareuk.org">fiona.loud@kidneycareuk.org</a>
Mr David Spensley	St Helier and Surrey Kidney Patients Association <a href="mailto:daspensley@btinternet.com">daspensley@btinternet.com</a>

**STATISTICS - SOUTHAMPTON CLINICAL TRIALS UNIT**

Dr Beth Stuart

Associate Professor of Medical Statistics  
Clinical Trials Unit  
University of Southampton  
[bls1@soton.ac.uk](mailto:bls1@soton.ac.uk)

**TRIAL COORDINATING CENTRE - NOTTINGHAM DIGESTIVE DISEASES CENTRE**

Ms Jennifer Dumbleton

Clinical Trial Manager  
Nottingham Digestive Diseases Centre  
University of Nottingham  
[jennifer.dumbleton@nottingham.ac.uk](mailto:jennifer.dumbleton@nottingham.ac.uk)

## SYNOPSIS

<b>Title</b>	Aspirin To Target Arterial events in Chronic Kidney Disease
<b>Acronym</b>	ATTACK
<b>Chief Investigators</b>	Professor Hugh Gallagher Professor Paul Roderick
<b>Objectives</b>	To test the hypothesis that the addition of 75mg aspirin once daily to usual care reduces the risk of major vascular events in patients with chronic kidney disease (CKD) who do not have pre-existing cardiovascular disease (CVD)
<b>Trial Configuration</b>	Open label, multi-centre study
<b>Setting</b>	Primary care
<b>Sample size estimate</b>	25,210 patients (12,605 per arm). A total of 1,827 major vascular events overall are required.
<b>Number of participants</b>	We expect to invite approximately 198,000 patients in order to recruit the 25,210 required.  Of these 12,605 will be randomised to aspirin 75 mg once daily and 12,605 to no additional treatment (with avoidance of aspirin).
<b>Eligibility criteria</b>	<u>Inclusion Criteria</u> 1. Males and females aged 18 years and over at the date of screening 2. Subjects with CKD (reduced eGFR and/or albuminuria) defined as: <ul style="list-style-type: none"> <li>• estimated glomerular filtration rate [eGFR] &lt;60mL/min/1.73m<sup>2</sup> for at least 90 days, and/or</li> <li>• kidney disease code on the GP electronic patient AND most recent eGFR in CKD-defining range (&lt;60mL/min/1.73m<sup>2</sup>), and/or</li> <li>• albuminuria or proteinuria (defined as urine albumin:creatinine ratio [ACR] ≥3mg/mmol, and/or urine protein:creatinine ratio [PCR] ≥ 15mg/mmol, and/or +protein or greater on reagent strip)</li> </ul>

	<ol style="list-style-type: none"> <li>3. Subjects who are willing to give permission for their paper and electronic medical records to be accessed by trial investigators</li> <li>4. Subjects who are willing to be contacted and interviewed by trial investigators</li> <li>5. Subjects who can communicate well with the investigator or designee, understand the requirements of the study and understand and sign the written informed consent</li> </ol> <p><u>Exclusion Criteria</u></p> <ol style="list-style-type: none"> <li>1. Subjects with CKD GFR category 5</li> <li>2. Subjects with pre-existing cardiovascular disease (angina, myocardial infarction, stroke, transient ischaemic attack (TIA), significant peripheral vascular disease, coronary or peripheral revascularisation for atherosclerotic disease)</li> <li>3. Subjects with a current pre-existing condition associated with increased risk of bleeding other than CKD</li> <li>4. Subjects currently prescribed anticoagulants or antiplatelet agent, or taking over the counter (OTC) aspirin continuously</li> <li>5. Subjects who are currently and regularly taking other drugs with a potentially serious interaction with aspirin</li> <li>6. Subjects with a known allergy to aspirin or definite previous clinically important adverse reaction</li> <li>7. Subjects with poorly controlled hypertension (latest recorded systolic blood pressure [BP] <math>\geq 180</math> mmHg and/or diastolic BP <math>\geq 105</math> mmHg)</li> <li>8. Subjects with other conditions which in the opinion of their General Practitioner (GP) would preclude prescription of aspirin in routine clinical practice, for example significant anaemia or thrombocytopenia</li> <li>9. Subjects who are pregnant or likely to become pregnant during the study period</li> <li>10. Subjects with malignancy that is life-threatening or likely to limit prognosis, other life-threatening co-morbidity, or terminal illness</li> <li>11. Subjects whose behaviour or lifestyle would render them less likely to comply with study medication</li> <li>12. Subjects in prison</li> <li>13. Subjects currently participating in another clinical trial of an investigational medicinal product or who have taken part in such a trial in the last three months (Covid-19 vaccine studies are acceptable)</li> </ol>
<p><b>Description of interventions</b></p>	<p>Suitable participants will be randomised to receive: 75mg non-enteric coated or dispersible aspirin once daily in addition to their usual medication; or no additional treatment and avoidance of aspirin.</p>
<p><b>Duration of study</b></p>	<p>The trial will continue until 1,827 major vascular events have occurred: this is anticipated approximately 2.5 years following the recruitment end date.</p>

<b>Randomisation and blinding</b>	Eligible participants will be randomised (open label randomisation) 1:1 to GP prescription of aspirin vs. no prescription, stratified by age, diabetes and CKD severity.
<b>Outcome measures</b>	<p><u>Primary outcome measure</u></p> <p>Time to first major vascular event from the date of randomisation. A major vascular event is defined as a primary composite outcome of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death (excluding confirmed intracranial haemorrhage and other fatal cardiovascular haemorrhage).</p> <p><u>Secondary outcome measures (all time to event except quality of life)</u></p> <p><u>Efficacy</u></p> <ol style="list-style-type: none"> <li>1. Death from any cause</li> <li>2. Composite outcome of major vascular event or revascularisation (coronary and non-coronary)</li> <li>3. Individual components of the primary composite endpoint</li> <li>4. Health-related quality of life</li> </ol> <p><u>Safety</u></p> <ol style="list-style-type: none"> <li>1. Composite outcome of intracranial haemorrhage (fatal and non-fatal), fatal extracranial haemorrhage and non-fatal major extracranial haemorrhage (adjudicated)</li> <li>2. Fatal and non-fatal (reported individually and as a composite) intracranial haemorrhage comprising: i) primary haemorrhagic stroke (to distinguish from haemorrhagic transformation of ischaemic stroke); ii) other intracranial haemorrhage (adjudicated). Intracranial haemorrhage will be sub-categorised as traumatic or non-traumatic.</li> <li>3. Fatal and non-fatal (reported individually and as a composite) major extracranial haemorrhage: i) upper gastrointestinal; ii) lower gastrointestinal; iii) sight-threatening ocular; iv) multiple trauma; v) other (adjudicated)</li> <li>4. Clinically relevant non-major bleeding (if hospitalised) (adjudicated)</li> <li>5. Composite outcome of fatal and non-fatal major extracranial haemorrhage and clinically relevant non-major bleeding (if hospitalised)</li> </ol> <p><u>Tertiary (exploratory) outcome measures (all time to event except hospitalisations)</u></p> <ol style="list-style-type: none"> <li>1. Transient ischaemic attack</li> <li>2. Unplanned hospitalisation</li> <li>3. Hospitalisation with heart failure</li> </ol>

	<ol style="list-style-type: none"> <li>4. New diagnosis of cancer (colorectal/other)</li> <li>5. Death due to cancer (where cancer is underlying cause of death)</li> <li>6. CKD progression</li> <li>7. New diagnosis of dementia</li> <li>8. Major non-traumatic lower limb amputation</li> </ol>
<p><b>Statistical methods</b></p>	<p>The primary outcome measure of time to first major vascular event will be analysed for the intention-to-treat (ITT) population. Deaths from other causes (including fatal bleeding) will be treated as competing events. Patients who do not experience a major vascular event will be censored at the date of last follow-up.</p> <p>All primary, secondary and tertiary time to event outcomes will be described using Kaplan-Meier curves or Cumulative Hazard plots for time to event outcomes involving competing risks for the ITT population. Analyses of time to event outcomes will be performed using Cox proportional hazards models or Competing Risk regression models, both unadjusted and adjusted for stratification factors: age, diabetes and CKD severity.</p> <p>The adjusted Competing Risk regression model for time to first major vascular event, with deaths from other causes (including fatal bleeding) treated as competing events, and patients who do not experience a major vascular event censored, will form the primary endpoint analysis model.</p> <p>Other secondary and tertiary endpoints will be assessed by arm using summary statistics (e.g. Pearson's <math>\chi^2</math> tests) in the ITT population.</p> <p>The amount of missing data and reasons for the incompleteness will be explored and presented overall i.e. not by group. If the amount of missing data is deemed too high and if appropriate (i.e. assuming the missing data is either missing at random [MAR] or missing completely at random [MCAR] and censoring assumed to be non-informative), multiple imputation will be performed accordingly, for which all covariates included in the multivariable model, together with the censoring/event indicator and the cumulative baseline hazard will be included in the multiple imputation model.</p>



## ABBREVIATIONS

ACR	Albumin:creatinine ratio
ADR	Adverse Drug Reaction
AE	Adverse Event
AR	Adverse Reaction
ASCEND	A Study of Cardiovascular Events in Diabetes
ASPREE	Aspirin in Reducing Events in the Elderly
ATC	Antithrombotic Trialists' Collaboration
ATTACK	Aspirin To Target Arterial Events In Chronic Kidney Disease
BNF	British National Formulary
BP	Blood pressure
cTn	Cardiac troponin
CI	Confidence interval
CKD	Chronic kidney disease
CKD-EPI	Chronic Kidney Disease Epidemiology Collaboration
CRF	Case Report Form
CRN	Clinical Research Networks
CVD	Cardiovascular disease
DMEC	Data Monitoring and Ethics Committee
EAC	Endpoint Adjudication Committee
ECG	Electrocardiogram
eGFR	Estimated glomerular filtration rate
EQ-5D-5L	EuroQol five dimensions (EQ-5D) 5 level
EPR	Electronic Patient Record
GCP	Good Clinical Practice
GDPR	General Data Protection Regulation
GI	Gastrointestinal
GP	General practitioner
Hb	Haemoglobin
HEAT	<i>Helicobacter</i> Eradication Aspirin Trial
HES	Hospital Episode Statistics
HOT	Hypertension Optimal Treatment
HR	Hazard ratio
HRQoL	Health-related quality of life
HTA	Health Technology Assessment
HRA	Health Research Authority
ICD	International Classification of Diseases
ICF	Informed Consent Form
ICH	International Conference on Harmonisation
IMD	Index of Multiple Deprivation
IMP	Investigational Medicinal Product
IPD	Individual Participant Data
IT	Information technology
ITT	Intention-to-treat
JPAD	Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes
KDIGO	Kidney Disease Improving Global Outcomes
LBBB	Left bundle branch block

MAR	Missing At Random
MCAR	Missing Completely At Random
MCV	Mean cell volume
MDRD	Modification of Diet in Renal Disease
MHRA	Medicines and Healthcare products Regulatory Agency
MI	Myocardial Infarction
NHS	National Health Service
NICE	National Institute for Health and Care Excellence
NIHR	National Institute for Health Research
NWIS	NHS Wales Informatics Services
ONS	Office for National Statistics
OPCS	Office of Population Censuses and Surveys
OR	Odds ratio
OTC	Over the counter
OXVASC	Oxford Vascular Study
PCI	Percutaneous coronary intervention
PCR	Protein:creatinine ratio
PPI	Proton pump inhibitor
PI	Principal Investigator
PIS	Participant Information Sheet
PSSRU	Personal Social Services Research Unit
QALY	Quality-adjusted life year
PEDW	Patient Episode Database for Wales
R&D	Research and Development
REC	Research Ethics Committee
RR	Relative risk
RRID	Renal Risk in Derby
SHARP	Study of Heart and Renal Protection
SAE	Serious adverse event
SCTU	Southampton Clinical Trials Unit
SOP	Standard Operating Procedures
SSC	Study Site Coordinator
SHEP	Systolic Hypertension in the Elderly Program
SPC	Summary of Product Characteristics
SUSAR	Suspected Unexpected Serious Adverse Reaction
TCR	The Computer Room
TIA	Transient ischaemic attack
TMG	Trial Management Group
TSC	Trial Steering Committee
UK-HARP-1	First United Kingdom Heart and Renal Protection Study
URL	Upper reference limit
USM	Urgent safety measure
USPSTF	US Preventative Services Task Force
WHO	World Health Organisation

# TABLE OF CONTENTS

<b>TRIAL PERSONNEL AND CONTACT DETAILS .....</b>	<b>2</b>
<b>SYNOPSIS .....</b>	<b>5</b>
<b>ABBREVIATIONS .....</b>	<b>9</b>
<b>1. BACKGROUND INFORMATION AND RATIONALE.....</b>	<b>14</b>
1.1 CHRONIC KIDNEY DISEASE	14
1.2 RELATIONSHIP BETWEEN CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR DISEASE	14
1.3 ASPIRIN AND THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE GENERAL POPULATION	15
1.4 ASPIRIN AND THE RISKS OF BLEEDING	17
1.5 INSIGHTS FROM RECENT PRIMARY PREVENTION STUDIES	20
1.6 ASPIRIN USE IN CHRONIC KIDNEY DISEASE: SPECIAL CONSIDERATIONS	21
1.6.1 BLEEDING RISK	21
1.6.2 CHRONIC KIDNEY DISEASE PROGRESSION	21
1.6.3 ASPIRIN RESISTANCE	22
1.6.4 GASTROPROTECTION IN CKD	22
1.7 EVIDENCE SUMMARY FOR ASPIRIN IN THE PRIMARY PREVENTION OF CVD IN CKD	23
1.8 IMPORTANCE OF THE TRIAL	24
1.9 SUMMARY OF RATIONALE AND SIGNIFICANCE	25
<b>2. AIM AND OBJECTIVES .....</b>	<b>25</b>
2.1 AIM OF THE TRIAL	25
2.2 PRIMARY OBJECTIVE	26
2.3 SECONDARY OBJECTIVES	26
<b>3. ENDPOINTS .....</b>	<b>26</b>
3.1 PRIMARY ENDPOINT	26
3.2 SECONDARY ENDPOINTS	27
3.3 TERTIARY ENDPOINTS	27
3.4 ASSESSMENT OF SAFETY	28
<b>4. TRIAL DESIGN.....</b>	<b>28</b>
<b>5. TRIAL PARTICIPANTS .....</b>	<b>28</b>
5.1 INCLUSION CRITERIA	28
5.2 EXCLUSION CRITERIA	29
5.3 CONTINGENCY PLAN FOR PARTICIPANT WELL-BEING	30
5.3.1 BEFORE RANDOMISATION	30
5.3.2 AFTER RANDOMISATION	31
5.4 WITHDRAWAL OF PARTICIPANTS FROM THE TRIAL	31
<b>6. TRIAL PROCEDURES .....</b>	<b>32</b>
6.1 INFORMATION TECHNOLOGY	32
6.2 RECRUITMENT	32
6.3 INFORMED CONSENT	33
6.4 CONSENT CONSULTATION	34

6.5 RANDOMISATION	35
6.6 ENDPOINT CAPTURE AND ADJUDICATION	35
6.7 DURATION OF THE TRIAL	37
6.8 STOPPING RULES AND DISCONTINUATION	37
6.8.1 TRIAL STOPPING RULES	37
6.8.2 INDIVIDUAL PARTICIPANT TREATMENT STOPPING CRITERIA	38
6.9 PILOT PHASE	39
6.9.1 PILOT STUDY AT 24 MONTHS	39
6.9.2 ASSESSMENT OF EVENT RATE	41
<b>7. TRIAL TREATMENT .....</b>	<b>41</b>
7.1 DETAILS OF INVESTIGATIONAL MEDICINAL PRODUCT	41
7.1.1 DESCRIPTION	41
7.1.2 MANUFACTURE/MARKETING AUTHORISATION	41
7.1.3 STORAGE	41
7.1.4 KNOWN SIDE EFFECTS	42
7.1.5 MANAGEMENT OF STUDY DRUG OVERDOSE	42
7.2 CONCOMITANT AND RESCUE MEDICATIONS AND TREATMENTS	42
7.3 ADHERENCE TO PRESCRIBED TREATMENT	42
7.4 URGENT SAFETY MEASURES	42
<b>8. TRIAL MANAGEMENT .....</b>	<b>43</b>
<b>9. STATISTICS.....</b>	<b>45</b>
9.1 SAMPLE SIZE	45
9.1.1 INITIAL SAMPLE SIZE ESTIMATE	44
9.1.2 DEFINITIVE SAMPLE SIZE ESTIMATE	45
9.2 ESTIMATION OF EFFECT SIZE	46
9.3 ESTIMATION OF EVENT RATE	47
9.4 DROPOUT RATE	50
9.5 DATA ANALYSIS	50
9.5.1 ASSESSMENT OF EFFICACY AND SAFETY	50
9.5.2 PROCEDURES FOR MISSING, UNUSED AND SPURIOUS DATA	52
9.5.3 DEFINITION OF POPULATIONS ANALYSED	52
9.5.4 ECONOMIC ANALYSIS	53
<b>10. ADVERSE EVENTS .....</b>	<b>54</b>
10.1 DEFINITIONS	54
10.2 REPORTING OF ADVERSE EVENTS	56
10.2.1 SERIOUS ADVERSE EVENTS	56
10.2.2 SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTION	57
10.2.3 DEVELOPMENT SAFETY UPDATE REPORTS	57
10.3 PREGNANCY	57
<b>11. ETHICAL AND REGULATORY ASPECTS .....</b>	<b>57</b>
11.1 ETHICS COMMITTEE AND REGULATORY APPROVALS	57
11.2 RECORDS	58
11.2.1 CASE REPORT FORMS (CRF)	58
11.2.2 SOURCE DOCUMENTS	58
11.3 DATA PROTECTION	58
<b>12. QUALITY ASSURANCE &amp; AUDIT .....</b>	<b>59</b>
12.1 INSURANCE AND INDEMNITY	59
12.2 TRIAL CONDUCT	59
12.3 TRIAL DATA	59

12.4 RECORD RETENTION AND ARCHIVING	59
12.5 DISCONTINUATION OF THE TRIAL BY THE SPONSOR	60
12.6 STATEMENT OF CONFIDENTIALITY	60
<b>13. PUBLICATION AND DISSEMINATION POLICY</b> .....	<b>60</b>
<b>14. USER AND PUBLIC INVOLVEMENT</b> .....	<b>60</b>
<b>15. STUDY FINANCES</b> .....	<b>60</b>
15.1 FUNDING SOURCE	60
15.2 PARTICIPANT STIPENDS AND PAYMENTS	60
<b>16. SIGNATURE PAGES</b> .....	<b>611</b>
<b>REFERENCES</b> .....	<b>62</b>
<b>APPENDIX 1: DEFINITION OF CLINICAL ENDPOINTS</b> .....	<b>719</b>

# 1. BACKGROUND INFORMATION AND RATIONALE

## 1.1 CHRONIC KIDNEY DISEASE

Chronic kidney disease (CKD) is defined as any abnormality of kidney function or structure with implications for health that is present for more than three months. It is classified according to the estimated glomerular filtration rate (eGFR) and urine albumin:creatinine ratio (ACR). The presence of an eGFR  $<60\text{mL}/\text{min}/1.73\text{m}^2$  or an ACR  $\geq 3\text{mg}/\text{mmol}^*$  for more than 90 days is diagnostic of CKD.

CKD is common, particularly in older people. The prevalence of CKD is estimated at 12-13% of adults from population data in England (1) and the USA (2). An important minority of people with CKD will develop end-stage renal disease, but the greatest significance of CKD is as a powerful and potentially modifiable risk factor for cardiovascular disease (CVD). People with CKD are categorised according to Kidney Disease Improving Global Outcomes (KDIGO) classification as being at moderate risk, high risk, or very high risk of CVD according to the level of both eGFR and ACR (3). In the USA 9.2%, 2% and 0.8% of adults are in the moderate risk, high risk and very high risk categories (4); these proportions were similar in the Health Survey of England (5).

## 1.2 RELATIONSHIP BETWEEN CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR DISEASE


Large-scale robust epidemiological data indicate that the risks of both all-cause and cardiovascular mortality in the general population increase where the eGFR is less than  $60\text{mL}/\text{min}/1.73\text{m}^2$ , and/or where the ACR is greater than  $1\text{mg}/\text{mmol}^*$ . These relationships are based upon the finding of a single eGFR and/or proteinuria test in the CKD-defining range. The risks are graded: compared with eGFR  $95\text{ mL}/\text{min}/1.73\text{ m}^2$ , adjusted hazard ratios (HR) for all-cause mortality were 1.18 (95% CI = 1.05-1.32) for eGFR  $60\text{mL}/\text{min}/1.73\text{m}^2$ , 1.57 (1.39-1.78) for  $45\text{mL}/\text{min}/1.73\text{m}^2$ , and 3.14 (2.39-4.13) for  $15\text{mL}/\text{min}/1.73\text{m}^2$ . ACR was associated with risk of mortality linearly on the log-log scale without threshold effects. Compared with ACR  $0.6\text{mg}/\text{mmol}$ , adjusted HR for all-cause mortality were 1.20 (1.15-1.26) for ACR  $1.1\text{mg}/\text{mmol}$ , 1.63 (1.50-1.77) for  $3.4\text{mg}/\text{mmol}$ , and 2.22 (1.97-2.51) for  $33.9\text{mg}/\text{mmol}$ . eGFR and ACR were multiplicatively associated with risk of mortality without evidence of interaction. Similar findings were recorded for cardiovascular mortality (6).

Albuminuria and eGFR are similarly predictive of mortality in high-risk population cohorts (7) and kidney disease cohorts (8), and in people with and without diabetes (9) and hypertension (10). These findings hold true in older people (11), both sexes (12) and across ethnic groups (13).

The pattern of vascular events in people with CKD varies according to disease severity. For those with the most severe impairment in GFR, and in particular those receiving renal replacement therapy, atherosclerotic events are less prevalent and arrhythmia and heart failure more important (14). However, in those where the GFR is less severely impaired, and where albuminuria indicates the presence of vascular damage and endothelial dysfunction (15), atherosclerotic events dominate.

\* where albuminuria measurements are not available measurements of urine protein:creatinine ratio or urine reagent strips can be substituted (3)

Figure 1. Cardiovascular mortality according to eGFR and ACR in combined general population and high risk cohorts (6)



Reproduced from CKD Prognosis Consortium, Matsushita K et al. *Lancet* 2010;375(9731):2073–81.

### 1.3 ASPIRIN AND THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE GENERAL POPULATION

In patients with cardiovascular disease, there is good evidence that antiplatelet therapy reduces the risk of subsequent vascular events (secondary prevention), and that overall these benefits outweigh the risks of major bleeding, which is the principal complication of therapy. A meta-analysis conducted by the Antithrombotic Trialists' Collaboration (ATC) showed that antiplatelet agents (primarily aspirin) reduced serious vascular events by 22% across five major high risk categories of patients (previous myocardial infarction (MI), acute MI, previous stroke or TIA, acute stroke and other high risk) in 195 trials: there were 7,705/71,912 (10.7%) serious vascular events in the antiplatelet treated group against 9,502/72,139 (13.2%) in adjusted controls. There was an expected increased risk of major bleeding: 95/47,158 fatal and 440/47,158 non-fatal major extracranial bleeds (1.1%) were seen in the antiplatelet group against (71+262)/47,168 (0.7%) in the controls (16). Antiplatelet therapy is recommended internationally for the secondary prevention of cardiovascular events in people with established cardiovascular disease.

In low-risk populations without pre-existing CVD the benefits of aspirin for the primary prevention of CVD are smaller and offset by an increased risk of bleeding. An ATC meta-analysis of six primary prevention studies reported a 12% proportional reduction in serious vascular events in a lower risk population (0.51% vs. 0.57% per annum) with aspirin (17). A meta-analysis in 2012 of nine randomised placebo-controlled trials indicated a clinically meaningful reduction in first myocardial

infarction but not in cardiovascular death with the use of aspirin in people without established cardiovascular disease: there were 2,107/52,145 (4.0%) events in the aspirin-treated group against 2,171/50,476 (4.3%) in the placebo group over a mean follow-up of six years. Aspirin reduced total cardiovascular events by 10% (odds ratio [OR] 0.9, 95% CI 0.85-0.96, number needed to treat 120). There was a 20% reduction in non-fatal myocardial infarction, but there was no significant reduction in cardiovascular death (0.99 [0.85-1.15]) and a significant increase in non-trivial bleeding events (1.31 [1.14-1.40]), number needed to harm 73) (18).

A 2013 HTA systematic review and overview of reviews also reported small absolute benefits and harms with the use of aspirin in primary prevention. In this analysis a risk reduction of approximately 10% for a composite outcome of cardiovascular death, non-fatal stroke and MI was observed, with an increase in the relative risks (RR) of bleeding: 37% for gastrointestinal (GI) bleeding (RR 1.37, 95% CI 1.15-1.62); between 54% (1.54 [1.30-1.82]) and 62% (1.62 [1.31-2.00]) for major bleeds; and between 32% (1.32 [1.00-1.74]) and 38% (1.38 [1.01-1.82]) for haemorrhagic stroke. Between 60 and 84 major vascular events were prevented per 100,000 patient-years of follow-up, with estimates of absolute rates of harm from aspirin use per 100,000 patient-years of follow-up of 99-178 for non-trivial bleeds, 46-49 for major bleeds, 68-117 for GI bleeds, and 8-10 for haemorrhagic stroke. Assuming equivalence of impact between cardiovascular events and bleeding episodes there was no net benefit in a low risk primary prevention population. The review emphasised a need for “further investigation in specific subgroups stratified according to reliable risk assessment tools” (19).

The difficulty of weighing the risks and benefits of aspirin for primary prevention is compounded by evidence that aspirin can reduce the risk of certain cancers. Among the 88,084 women and 47,881 men from the Nurses' Health Study (1980-2010) and Health Professionals Follow-up Study (1986-2012) who underwent follow-up for as long as 32 years, 20,414 cancers among women and 7,571 cancers among men were documented. Compared with non-regular use, regular aspirin use was associated with a lower risk for overall cancer (RR 0.97, 95% CI 0.94-0.99), which was primarily owing to a lower incidence of GI tract cancers (0.85 [0.80-0.91]), especially colorectal cancers (0.81 [0.75-0.88]) (20). In another individual patient data meta-analysis, aspirin was associated with a reduction in cancer mortality (RR 0.66; 95% CI, 0.50-0.87), which translated to approximately 200 fewer cancer deaths (300 fewer to 80 fewer) per 100,000 patient-years (21). The effect of the use of aspirin for primary prevention on all-cause mortality has also been evaluated, with a relatively consistent probable 6-8% reduction over 10 years reported (19,22,23).

Despite the existence of a substantial body of evidence it therefore remains uncertain whether and under what circumstances aspirin should be used for primary prevention. In 2016 the US Preventative Services Task Force (USPSTF) published recommendations on aspirin use for the primary prevention of CVD (and colorectal cancer). The recommendations were based upon three commissioned systematic reviews and a microsimulation model to systematically estimate the balance of risk and harms. The USPSTF concluded that aspirin should be initiated for the primary prevention of CVD and colorectal cancer in people aged 50-59 with a 10-year CVD risk of at least 10%, no increased risk of bleeding, and a life expectancy of 10 years or more; the review recommended that the decision for people aged 60-69 should be individualised, and that there was insufficient evidence to guide a recommendation in people aged 70 and above (24). An evidence-based clinical decision support tool has recently been developed to support implementation; the algorithm takes advantage of age- and sex-specific results from randomised trials to determine the



net benefit of aspirin but does not makes reference to kidney disease (25). The European Society of Cardiology currently recommend that “aspirin be considered in the primary prevention of cardiovascular disease in both sexes at a level of risk of major cardiovascular events (death, MI, and stroke) of >2 per 100 subject-years, provided they have no clear evidence of increased risk of bleeding (GI bleeding or peptic ulcer disease and no concurrent use of other medications that increase bleeding risk)” (26).

## 1.4 ASPIRIN AND THE RISKS OF BLEEDING

An increased bleeding tendency is the most important complication of aspirin therapy. Bleeding most often occurs in the GI tract, where it is infrequently fatal but may be disabling particularly in older people (27). Intracranial bleeding is much rarer but more frequently fatal and/or disabling.

The results of an individual participant data meta-analysis including 95,000 individuals from six large primary prevention trials (British Doctor Study, US Physicians’ Health Study, Thrombosis Prevention Trial, Hypertension Optimal Treatment Trial, Primary Prevention Project, and Women’s Health Study) have been used to derive and compare absolute risk estimates of cardiovascular disease and bleeding for people at low, moderate and high cardiovascular risk according to the Framingham risk score (28). To derive baseline control group risk estimates it was assumed that patients at low, moderate and high risk of cardiovascular disease had a 5%, 15%, and 25% 10-year risk respectively of an MI (combined fatal and non-fatal). It was assumed that people at low, moderate and high cardiovascular risk would be in the same risk categories for bleeding. The control group risk estimates were adjusted to assume a 20% overestimation of coronary heart disease risk (and bleeding risk) by the Framingham score. To estimate the probability of each outcome, the authors used the observed ratio of non-fatal MI to fatal MI to nonfatal stroke to major extracranial bleeding events in an individual participant data meta-analysis assessing benefits and harms of aspirin in primary prevention of cardiovascular disease (17). Data were reported as absolute effects over 10 years per 1,000 patients. The Framingham risk score does not separate non-fatal and fatal MI, and these were estimated using the ratio of non-fatal: fatal MI from the individual participant data meta-analysis of approximately 2:1. Overall aspirin increased the risk of major bleeding by 54%. The data on major extracranial bleeding and non-fatal MI are summarised in Table 1 as absolute effects per 100,000 patient-years:

Table 1. Absolute risk differences of major bleeding and non-fatal MI with aspirin used for the primary prevention of CVD (28)

Outcome	Population	Anticipated absolute risk without aspirin per 100,000 patient-years	Anticipated absolute risk difference with aspirin per 100,000 patient-years (95% CI)
<b>Non-fatal MI</b>	Low CV risk	270	60 fewer (from 80 fewer to 40 fewer)
	Moderate CV risk	830	190 fewer (from 260 fewer to 120 fewer)
	High CV risk	1,360	310 fewer (from 420 fewer to 190 fewer)
<b>Major extracranial bleed</b>	Low CV risk	80	40 more (from 20 more to 70 more)
	Moderate CV risk	240	160 more (from 70 more to 200 more)
	High CV risk	400	220 more (from 120 more to 330 more)

In comparison, the use of aspirin in people with established coronary artery disease prevents 740 (460-940) non-fatal MI per 100,000 patient-years at a cost of 500 (80-1420) major bleeds (28).

Critical in all these analyses is the estimation of the baseline risk of bleeding. As a part of the evidence supporting their 2016 recommendations on aspirin for primary prevention (24) the USPSTF conducted a systematic review of aspirin-associated major GI bleeding; this included cases leading to death, those requiring hospitalisation or transfusion, or those described by the trial investigator as serious (29). Their data were derived from eight primary prevention studies, with simulations illustrating a range of projected excess bleeding cases with low-dose aspirin use. Because of the limitations of study reporting, lower GI bleeds were not adequately represented. The risk groups were defined as low (minimum), median, high and highest (maximum) for each outcome based upon the control group rate excluding zeros and outliers from the primary prevention studies. The absolute effects are summarised in Table 2.

**Table 2. Estimated excess rates of GI bleeding events with aspirin used (for <10 years) according to CVD risk group for the primary prevention of CVD (29)**

<b>Outcome</b>	<b>Population</b>	<b>Baseline risk without aspirin per 100,000 patient-years</b>	<b>Anticipated additional risk with low-dose aspirin per 100,000 patient-years (95% CI)</b>
<b>Major GI bleed</b>	Low risk	23	13 more (from 7 more to 22 more)
	Median risk	49	28 more (from 14 more to 40 more)
	High risk	58	34 more (from 17 more to 55 more)
	Highest risk	104	60 more (from 30 more to 99 more)

For haemorrhagic stroke the USPSTF reported that low-dose (<100mg) aspirin was associated with a possible but non-significant increase in haemorrhagic stroke of 27% (OR 1.27, 95% CI 0.96-1.68). The absolute effects were 0, 11 more (from 2 fewer to 29 more) and 34 more (from 5 fewer to 86 more) per 100,000 patient-years in low, high and highest risks group respectively (29).

Although assumptions around baseline bleeding rate are clearly important when applying these trial-based averages based on selected groups to the unselected general population, these data suggest an overall benefit of aspirin in higher CV risk populations. As the absolute risk of CVD rises both the benefits and bleeding complications of aspirin increase, with the benefits often exceeding the risks in people with an estimated risk of CVD above 1% per year (25). However, determination of the net clinical benefit of aspirin is more complex than a simple numerical comparison between these variables, and it is possible that a binary approach may underestimate the true benefits. In particular weighing the importance of ischaemic and bleeding events is not straightforward. Most models attribute equal weight in terms of patient preferences to a non-fatal cardiovascular event and to major bleeding. However it has been argued that with the exception of haemorrhagic stroke this is hard to concede (26). Furthermore, although clearly important in terms of consequences for deaths and disabilities, haemorrhagic stroke is much less common than major GI bleeding, and its fatal consequences are already included within estimates of total deaths associated with aspirin, which point toward a net benefit (19,22,23,26).

Survivors of an acute MI have a 30-day mortality of around 5% (30). The one-year mortality in patients enrolled in the GUSTO-IIb trial was in the order of 10% (31). UK national data (Office for National Statistics (ONS) and Hospital Episode Statistics (HES)) for 2010 reveal a 30-day case

fatality rate for MI of around 31% overall and 12% in those admitted to hospital (32). Against this, a recent systematic review and meta-analysis of 11 randomised controlled trials of aspirin which reported fatal and non-fatal GI bleeding found that although aspirin increased the risk of bleeding by 60%, a similar effect to that reported elsewhere, the risk of fatal bleeding was not significantly elevated, and the fatality rate in the event of GI bleeding was significantly reduced in people taking aspirin, perhaps because of unmasking of GI pathology by aspirin early in the natural history (33). The incidence of GI bleeding attributable to aspirin may also decrease over time. Within the first month of aspirin taking the risk is increased more than four-fold (34,35) but it then reduces rapidly, and after three to five years of use there does not appear to be a significant excess of GI bleeds (36).

The risk-benefit equation derived from historical primary prevention studies will also be modified by the use of concomitant medications in modern clinical practice. Both proton pump inhibitors and H2 receptor antagonists reduce aspirin-induced GI bleeding (see below). Rates of bleeding on aspirin are also significantly lower in patients taking statins, with an incidence rate ratio for hospitalisation for major bleeding of 0.67 (0.62-0.71) from trials and cohort studies (29), although to what extent this benefit may be offset by a reduction in absolute benefits remains unclear.

Data from cohort studies have not unexpectedly revealed higher bleeding rates than those from randomised trials due to the inclusion of less selected populations. A large-scale general population cohort reported 198 extra (558 overall) major GI and intracranial bleeds per 100,000 patient-years with aspirin use (for any indication); the risks rose sharply with age, with 108, 136, 226 and 367 additional bleeds per 100,000 patient years at age 50-59, 60-69, 70-79 and  $\geq 80$  respectively (37). The Oxford Vascular Study (OXVASC) also reported high rates of major bleeding, 187 major bleeds in 13,509 patient-years, in a cohort of patients taking long-term aspirin for secondary prevention of CVD followed for up to 10 years. The bleeding rates in the OXVASC participants, 50% of whom were aged 75 and over, are higher than those reported in randomised trials of aspirin in secondary prevention conducted in younger patients, which in turn are greater than those observed in primary prevention trials. The risk of non-major bleeding was unrelated to age, but major bleeding increased steeply with age ( $\geq 75$  years HR 3.10 95% CI 2.20-4.24), particularly for fatal bleeds (5.53 [2.65-11.54]). In patients younger than 75 years, the ratio of major bleeds to ischaemic events was similar to the ratios in previous aspirin secondary prevention trials (pooled ratio 0.19 [0.17-0.21]). However, the ratio in OXVASC increased with age (75-84 years 0.32 [0.23-0.43];  $\geq 85$  years 0.46 [0.32-0.67]), and the risk of major bleeds estimated to be attributable to antiplatelet treatment approached the risk of ischaemic events estimated to have been prevented (27).

It should be emphasised that the OXVASC cohort are very different to the population anticipated in ATTACK, in that OXVASC follows an unselected high risk secondary prevention group that also included people taking dual antiplatelet agents. In patients with TIA and ischaemic stroke, long-term recommended antiplatelet treatment was aspirin 75mg daily plus dipyridamole 200mg twice daily and in those with myocardial infarction standard initial treatment was with aspirin plus clopidogrel for 6–12 months (although the results were similar in analyses excluding bleeds occurring during treatment with aspirin plus clopidogrel). OXVASC also included patients switched from oral anticoagulants to antiplatelet therapy.

Furthermore, it is possible to mitigate these risks. Peptic ulcer bleeding in patients treated with low-dose aspirin is substantially reduced by the co-prescription of proton pump inhibitors (PPI) (38). A 2015 meta-analysis indicated that PPIs were superior to placebo (OR 0.26, 95% CI 0.14-0.49) and H2-antagonists (0.36 (0.15-0.87)) in the prevention of GI bleeding associated with low-dose aspirin (39). The risk reduction with PPIs is substantial in patients with risk factors for GI bleeding (40). Although overall the use of PPIs reduces upper GI bleeds by 70-90%, uptake in clinical practice is low. This is a key factor modifying the trade-off between benefit and risk from studies such as OXVASC (where only 24% were prescribed PPIs (27)).

## 1.5 INSIGHTS FROM RECENT PRIMARY PREVENTION STUDIES

More recently, the results of three large studies have added to the evidence base for aspirin in primary prevention. These trials are summarised in Table 3:

Table 3. Recent aspirin cardiovascular prevention trials

<b>Trial</b>	<b>Study population</b>	<b>Characteristics</b>	<b>Results</b>
<b>A Study of Cardiovascular Events in Diabetes (ASCEND) (41,42)</b>	Individuals with diabetes (primary prevention)	Design - Placebo-controlled randomised controlled trial  Primary endpoint - Serious vascular events (composite of non-fatal MI, non-fatal stroke or TIA, or vascular death, excluding confirmed cerebral haemorrhage)  n=15,480	Primary endpoint HR 0.88 (0.79-0.97)  Absolute effects - Serious vascular events: 1.30% per year in controls vs. 1.15% in aspirin-treated - Over 7.4 years: 1.1% reduction in serious vascular events 0.9% increase in major bleeding
<b>Aspirin in Reducing Events in the Elderly (ASPREE) (43–45)</b>	Healthy participants aged 65 years and above	Design - Placebo-controlled randomised controlled trial  Primary endpoint - Composite of death from any cause or incident, dementia or persistent physical disability  n=19,114	Primary endpoint HR 1.01 (0.92-1.11)  Major adverse cardiovascular events (fatal coronary heart disease, excluding death from heart failure, non-fatal MI, fatal or non-fatal stroke) (non-prespecified) HR 0.89 (0.77-1.03)  Absolute effects - Major adverse cardiovascular events: 0.88% per year in controls vs. 0.78% per year in aspirin-treated - Major bleeding: 0.62% per year in controls vs. 0.86% per year in aspirin-treated
<b>A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE) (46,47)</b>	People at moderate risk of CVD (primary prevention)	Design - Placebo-controlled randomised controlled trial  Primary endpoint - Major vascular events (composite of MI, stroke, CV death, unstable angina, TIA)  n=12,546	Primary endpoint HR 0.96 (0.81-1.13)  Absolute effects - Major vascular events: 0.90% per year in controls vs. 0.86% per year in aspirin-treated - Gastrointestinal bleeding: 0.09 % per year in controls vs. 0.19% per year in aspirin-treated

The results were similar to those in the historical primary prevention studies in that the rates of cardiovascular events was low (around 1% per annum), and the benefits of aspirin were modest and balanced by an increase in major bleeding. They do not support a change in practice such that aspirin should be offered for primary prevention in the patient groups studied.

However the findings are of limited relevance to the hypothesis to be tested in ATTACK, because the patients in ASCEND, ASPREE and ARRIVE were at lower risk than that we anticipate in ATTACK, and there were only small numbers of people with CKD in the three trials. In ASCEND 12% of the enrolled subjects had an eGFR <60 mL/min/1.73m<sup>2</sup> and 13% an ACR ≥3 mg/mmol (48). 19% of the participants in ASPREE had an eGFR <60 mL/min/1.73m<sup>2</sup> (49). The presence of severe renal disease was an exclusion criterion in ARRIVE (46).

These three 2018 trials were also included in an updated meta-analysis of 13 aspirin trials for primary prevention published in 2019. In a population with a median age of 62 years and a median baseline risk of the primary cardiovascular outcome of 9.2%, aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (571 per 100,000 patient years with aspirin and 614 per 100,000 patient years with no aspirin, HR 0.89 [0.84-0.95]). Aspirin use was also associated with an increased risk of major bleeding events compared with no aspirin (231 per 100,000 patient years with aspirin and 164 per 100,000 patient years with no aspirin, HR 1.43 [1.30-1.56]) (50). The rate of intracranial haemorrhage was 67 and 51 per 100,000 patient years with aspirin and no aspirin respectively (51).

## **1.6 ASPIRIN USE IN CHRONIC KIDNEY DISEASE: SPECIAL CONSIDERATIONS**

### **1.6.1 BLEEDING RISK**

In CKD one might expect substantial absolute benefits even if the relative reductions in the risks of CVD were no greater than in the general population. However it is not clear to what extent any benefits may be offset because people with CKD are also at increased risk of bleeding. Many people with CKD are elderly. There are additional specific mechanisms through which the bleeding tendency may be increased in CKD, including defective platelet adhesion to the sub-endothelium, defective platelet aggregation, and other intrinsic platelet defects (52). A Cochrane review (which included patients at all stages of CKD, including those receiving renal replacement) reported that the use of antiplatelet agents in people with CKD conferred an increased relative risk of major (27 studies, RR 1.33, 95% CI 1.10-1.65) and minor bleeding (18 studies, 1.49 (1.12-1.97)) compared with placebo/control. The definitions of bleeding employed within the included studies were variable. The relative risks of major bleeding due to aspirin appeared no higher than those in the non-CKD population, although the absolute excess risks were higher due to the higher risks in the CKD control groups (53). The safety of low-dose aspirin in CKD was also explored in the First United Kingdom Heart and Renal Protection Study (UK-HARP-1). 448 patients were randomly assigned 20mg simvastatin vs. placebo and 100mg aspirin vs. placebo in a 2x2 factorial design. Allocation to aspirin was not associated with an excess of major bleeds in one year of follow-up (though it was underpowered); there was a three-fold excess of minor bleeding episodes (54).

### **1.6.2 CHRONIC KIDNEY DISEASE PROGRESSION**

Aspirin-induced cyclooxygenase acetylation may inhibit prostaglandin-induced renal vasodilatation and reduce renal blood flow. Most studies show no association between therapy with low-dose aspirin and renal injury. Data from large scale cohort studies in healthy people does not show a

relationship between long-term aspirin use and the development of renal dysfunction (55,56). In people with CKD propensity matched analyses have suggested an association between low-dose aspirin use and CKD progression (57). However, this has not been borne out in cardiovascular trials of low-dose aspirin that included patients with CKD (58,59).

### **1.6.3 ASPIRIN RESISTANCE**

It has been reported that high on-treated platelet activity (aspirin resistance) is more common in people with CKD than the general population (60,61), although other studies have found that this finding varies according to the technique employed to measure platelet activity (62) and that the effect may no longer be significant after adjustment for co-morbidities (63). There are some data suggesting that antiplatelet therapy with clopidogrel in people with mild or moderate CKD after percutaneous coronary intervention might not have the same beneficial effect as it does in patients with normal renal function (64). It remains uncertain whether any reduced antiplatelet efficacy of aspirin in CKD leads to clinically important treatment failure.

### **1.6.4 GASTROPROTECTION IN CKD**

2010 guidelines on the prevention of aspirin-induced upper GI bleeding recommend concomitant use of PPI in people with a past history of upper GI bleeding or multiple risk factors for GI bleeding (advanced age, concomitant use of warfarin, steroids, or NSAIDs, *Helicobacter pylori* infection). Kidney disease is not included as a risk stratification factor. It was added that H2-antagonists “may be a reasonable alternative in patients at lower risk for GI bleeding” (40).

Since these guidelines were produced, an increased incidence of acute interstitial nephritis in users of PPI has been reported. The absolute risks are small, with a nationwide nested case-control study revealing an incidence of 12.0 (95% CI 9.1-15.5) and 1.7 (0.9-1.9) per 100,000 patient-years in current and past users respectively. Observational data have also revealed associations between PPI and incident CKD (65) and of adverse chronic renal outcomes (decline in eGFR of more than 30% and end stage renal disease) in those without intervening acute kidney injury (66), although whether such pharmacoepidemiological data should be used to imply a causal link has been recently challenged (67).

Recent data have also provided some support for the role of H2-antagonists in gastroprotection. In a randomised controlled trial of 270 high-risk aspirin users (with a history of endoscopically confirmed ulcer bleeding), 7.9% (95% CI 4.2-14.7) of patients receiving an PPI (Rabeprazole) reached the primary endpoint of recurrent bleeding or ulceration at 12 months compared with 12.4% (7.4-20.4) receiving a H2-antagonist (Famotidine). The difference was not statistically significant. The authors concluded that the incidence of recurrent bleeding in high-risk users was comparably low with PPI and H2-antagonists, and that, although a small difference in efficacy could not be excluded, H2-antagonists could be considered as alternative gastroprotective agents in high-risk patients (68).

The risk of bleeding in people with CKD is likely to vary with both age and CKD category. Such heterogeneity is not captured by current clinical guidelines. ATTACK is a pragmatic study and a real-world approach will also be applied to this area of clinical uncertainty. The decision to introduce gastroprotection, and the choice of any gastroprotective agent, is not mandated under the Protocol, but rather will be at the discretion of the treating GP. Our GP training materials will provide the necessary information to support a process of shared decision-making, highlighting factors that are likely to increase the risks of bleeding.

## 1.7 EVIDENCE SUMMARY FOR ASPIRIN IN THE PRIMARY PREVENTION OF CVD IN CKD

There is currently insufficient evidence to recommend the use or avoidance of aspirin for the primary prevention of CVD in CKD as data on the use of antiplatelet agents in the specific setting of primary prevention in CKD are limited. The literature suggests that the efficacy of aspirin in CVD prevention is at least as great in people with CKD as the general population but the risks may also be greater, and so uncertainty remains about the net balance of benefit and risk.


The effect of aspirin on cardiovascular outcomes in CKD was examined in a Cochrane review that examined all randomised trials of antiplatelet use in CKD, including studies on patients undergoing coronary interventions and trials where the primary outcome measure concerned kidney disease progression and dialysis access patency. The relative risk reductions were smaller than those observed in secondary prevention in the non-CKD population: overall antiplatelet agents reduced the risk of MI (17 studies, RR 0.87, 95% CI 0.76-0.99), but not all-cause mortality (30 studies, 0.93 [0.81-1.06]), cardiovascular mortality (19 studies, 0.89 [0.70-1.12]) or stroke (11 studies, 1.00 [0.58-1.72]) (53). 21,460 patients from a total of 44 studies of antiplatelet vs. placebo were included in the review. However, and critically with respect to the hypothesis addressed by this trial, data on the effects of antiplatelet agents in primary prevention in CKD were available only from a post-hoc subgroup analysis of a single study, the Hypertension Optimal Treatment (HOT) Trial. In the overall HOT study population, aspirin reduced the risk of major cardiovascular events by 15%, but did not affect total mortality or cardiovascular mortality (69). However, there was evidence of significant heterogeneity by eGFR. Major cardiovascular events were reduced by 9% (95% CI -9% to 24%), 15% (-17% to 39%), and 66% (33% to 83%) for patients with baseline eGFR of  $\geq 60$ , 45 to 59, and  $< 45$  mL/min/1.73m<sup>2</sup> respectively ( $p$  for trend = 0.03). In those with an eGFR of 45-59 mL/min/1.73m<sup>2</sup>, 8 (-7 to 22) major cardiovascular events were prevented per 1,000 patients treated for 3.8 years, at a cost of 4 (-2 to 10) major bleeds; at eGFR  $< 45$  mL/min/1.73m<sup>2</sup>, 76 (31 to 121) events were prevented, at a cost of 27 (-1 to 55) bleeds. Total mortality was not affected in the CKD group as a whole but was significantly reduced in those subjects with eGFR  $< 45$  mL/min/1.73m<sup>2</sup>, although only 2.9% of the population had an eGFR  $< 45$  mL/min/1.73m<sup>2</sup> and reporting of bleeding episodes was imprecise (58). It is also unclear how generalisable the findings are to non-hypertensive people with CKD as the criteria for entry into HOT were BP-based (69).

The primary prevention of CVD in CKD has been the subject of a recent systematic review. Three trials were identified from a total of 1,314 records screened; two of these provided previously unpublished data. 4,468 adults with pre-end stage CKD and no history of CVD were included. There were 16,740 person-years of follow-up. A random effects model was used to pool the data. The trials were assessed as showing medium to high levels of risk of bias, largely related to endpoint assessment and suboptimal identification of CKD. Only one trial, HARP (54), was CKD-specific; it did not report cardiovascular events in aspirin and placebo groups. There was no pre-specified CKD analysis in the other two studies, HOT and the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial (70). Neither JPAD nor HOT provided data on albuminuria, a potent amplifier of vascular risk.

Overall there was no statistically significant reduction in major cardiovascular events (RR 0.92, 95% CI 0.49-1.73,  $p = 0.79$ ). There was a high level of heterogeneity ( $I^2 = 71\%$   $p = 0.06$ ). In HOT there were 76/1791 cardiovascular events in the aspirin-treated group and 110/1,828 in controls, with a

risk ratio of 0.71 (0.53-0.94). The numbers were smaller and the findings divergent in JPAD, with 24/342 and 15/290 events in aspirin and control groups respectively and a risk ratio of 1.36 (0.73-2.54). Overall there were 100/2,241 CVD events in aspirin-treated patients across the included studies and 125/2,228 in controls. Mortality was non-significantly reduced in the aspirin group (RR 0.74, 0.55-1.00,  $p = 0.05$ ,  $I^2 0\%$ ):

**Figure 2. Systematic review of aspirin for the primary prevention of CVD in CKD. Forest plot of risk ratios for CVD events using a random effects model and Mantel-Haenszel method (71)**



*Reproduced from Major RW et al. Atherosclerosis 2016;251:177-82*

Aspirin increased the risk of major bleeding (34/2,241 episodes aspirin-treated patients vs. 17/2,228 in controls (RR 1.98, 1.11-3.52,  $p = 0.02$ ,  $I^2 0\%$ )). The authors of the systematic review concluded that the limitations of the evidence highlighted the need for definitive CKD-specific randomised controlled trials (71). A CKD subgroup analysis of participants in the ASPREE trial was published in 2021. There was no clear reduction in cardiovascular events but the analysis was not adequately powered ( $n = 4758$  patients) to confirm or exclude an effect (72). An accompanying editorial concluded that studies such as ATTACK were still required (73).

## 1.8 IMPORTANCE OF THE TRIAL

The question of whether aspirin should be used for primary prevention in CKD is of high importance given the affordability of aspirin, the wide acceptance of aspirin as potentially therapeutic by patients, and the high risk for CVD in CKD (74).

The burden of CVD in CKD is substantial. Overall CVD is responsible for about one-third of all deaths in the UK. It can have a serious impact upon quality of life and cause considerable disability. CKD is included as a vascular condition within the Department of Health's CVD Outcomes Strategy (75). The financial impact of CVD in CKD is large: assuming unit costs of £12,200 for a stroke and £7,734 for an MI and incidence of stroke and MI of 12.0 and 11.9 per 1000 patient-years respectively in people with CKD (76), the annual costs of strokes and MI in people with CKD in England is in the order of £1bn.

Our understanding of how to reduce cardiovascular risk in CKD is limited. The Study of Heart and Renal Protection (SHARP) demonstrated that primary prevention with simvastatin and ezetimibe reduced major atherosclerotic events in people with CKD. 13.4% of a control group (mean eGFR of 27mL/min/1.73m<sup>2</sup>) experienced a major atherosclerotic event (including revascularisation) in SHARP over a median follow-up of 4.9 years (77). Even in a lower risk UK primary care cohort (mean eGFR 52mL/min/1.73m<sup>2</sup>, 84% without albuminuria) the annual mortality from CVD in those without pre-existing CVD was as high as 0.7% (78,79). Evidence on other approaches to prevent



CVD in CKD is therefore urgently required. In 2014 the National Institute for Health and Care Excellence (NICE) made a research recommendation for a definitive trial of aspirin for primary prevention of CVD in people with CKD (80).

The results of this trial, whether positive or negative, will provide the evidence to improve clinical outcomes in large numbers of people. Most people with CKD who do not have CVD are not currently prescribed aspirin. In a UK primary care cohort including 31,056 individuals with an eGFR <60mL/min/1.73m<sup>2</sup> 70% were recorded as having a history of pre-existing CVD; aspirin was prescribed to 68% of individuals with CKD and CVD and to 22% with CKD and no CVD (81). A positive result from ATTACK would imply that aspirin should be offered to more than 3 million additional people in the UK (excluding those with a contraindication or taking OTC). If use of aspirin for primary prevention of CVD in people with CKD results in a relative reduction of 12.5% in the risk of CVD, 50,000 additional major vascular events over five years may be prevented in this group. Conversely a negative trial result would provide definitive evidence to stop aspirin in one million people who are now taking it for primary prevention. If our hypothesis is correct the costs of CVD averted in people participating in the trial alone would cover approximately 50% of the research costs of the study.

## **1.9 SUMMARY OF RATIONALE AND SIGNIFICANCE**

1. CKD is a very common long-term condition and powerful risk factor for CVD. The healthcare costs associated with CVD in CKD are substantial
2. In people with pre-existing CVD (the group at highest risk of major vascular events), aspirin is of proven benefit in the prevention of heart attack and stroke
3. In lower risk groups where the rates of heart attack and stroke are much lower, the benefits of aspirin in preventing CVD are largely balanced by an increased risk of bleeding
4. People with CKD are at greatly increased risk of CVD and so the absolute benefits of aspirin are likely to be greater than in lower risk groups even if the relative benefits are the same. Post-hoc evidence from the HOT trial also suggests the relative benefits may be greater in the CKD population. However the absolute risk of bleeding may also be higher
5. In the UK it is likely that there are more than 3 million people with CKD and no CVD who are not prescribed aspirin but around one million that are receiving aspirin in the absence of definitive evidence. The results of this trial, whether positive or negative, will therefore be directly and immediately applicable to very large numbers of patients
6. This will be the first definitive trial of aspirin as primary CVD prevention in CKD patients. As such the research will be of great interest to clinicians, guideline groups and policy-makers, in the UK and globally, particularly given the high and rising prevalence of CKD. The low cost of aspirin means that a positive result will also be of relevance to Low and Middle Income Countries and the impact not diluted in countries such as the United States by issues around income or insurance status

## **2. AIM AND OBJECTIVES**

### **2.1 AIM OF THE TRIAL**

The research aims to demonstrate whether the addition of low-dose (75mg non-enteric coated or dispersible) aspirin to usual care reduces the risk of major vascular events (excluding confirmed intracranial haemorrhage and other fatal cardiovascular haemorrhage) in people with CKD who do

not have pre-existing CVD, and whether and to what extent the benefits outweigh any harms due to an increased risk of bleeding.

## **2.2 PRIMARY OBJECTIVE**

The primary objective of the research is to test the hypothesis that low-dose (75mg non-enteric coated or dispersible) aspirin reduces the risk of major vascular events (excluding confirmed intracranial haemorrhage and other fatal cardiovascular haemorrhage) (primary endpoint) in people with CKD who do not have pre-existing CVD.

## **2.3 SECONDARY OBJECTIVES**

The secondary objectives of the research are:

1. To assess the impact of the addition of low-dose aspirin to usual care in people with CKD and no CVD on the incidence of intracranial bleeds, major extracranial bleeds, and inpatient clinically relevant bleeds not meeting major bleeding criteria
2. To assess the impact of the addition of low-dose aspirin to usual care on other secondary and tertiary endpoints including: all-cause mortality; combined endpoint of major vascular events and revascularisation (coronary and non-coronary); individual components of the primary endpoint; TIA; hospitalisation for heart failure, unplanned hospitalisation; new diagnosis of cancer (colorectal/other); death due to cancer (where cancer is underlying cause of death); major non-traumatic lower limb amputation; CKD progression; health-related quality of life (HRQoL), dementia
3. To examine a priori the effect of low-dose aspirin on primary, secondary and tertiary endpoints in various subgroups of people with CKD: high risk and very high risk CKD as defined by KDIGO (KDIGO 2012); diabetes; age  $\geq 70$ ; eGFR  $< 45 \text{ mL/min/1.73m}^2$ ; ACR  $\geq 3 \text{ mg/mmol}$ ; ACR  $> 30 \text{ mg/mmol}$
4. To assess the cost-utility of low-dose aspirin compared with usual care

## **3. ENDPOINTS**

Follow-up for the major outcomes in ATTACK is based upon routinely collected hospital, GP and national mortality data. This will allow a full intention-to-treat (ITT) analysis on all participants who are randomised, with the exception of those who both withdraw from the study and remove their consent for data linkage or who move abroad. Where patients move within the UK to another ATTACK practice, outcomes recorded on the primary care Electronic Patient Record (EPR) will continue to be collected as these data are linked to the NHS number. Where the patient moves to a non-ATTACK practice searches will not be possible but outcome data will continue to be collected via linked secondary care and mortality data and by patient self-reporting.

### **3.1 PRIMARY ENDPOINT**

The primary outcome measure is the time to first major vascular event from the date of randomisation. A major vascular event is defined as a primary composite outcome of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death (excluding confirmed intracranial haemorrhage and other fatal cardiovascular haemorrhage). Deaths from other causes (including

fatal bleeding) will be treated as competing events. Patients who do not experience a major vascular event will be censored at the date of last follow-up.

### 3.2 SECONDARY ENDPOINTS

The secondary endpoints are listed below. These will be time to event except health-related quality of life (details in section 9.5.1).

#### Efficacy

1. Death from any cause
2. Composite outcome of major vascular event or revascularisation (coronary and non-coronary)
3. Individual components of the primary composite endpoint
4. Health-related quality of life

#### Safety

1. Composite outcome of intracranial haemorrhage (fatal and non-fatal), fatal extracranial haemorrhage and non-fatal major extracranial haemorrhage (adjudicated)
2. Fatal and non-fatal (reported individually and as a composite; also subcategorised as traumatic or non-traumatic (82)) intracranial haemorrhage comprising:
  - i) primary haemorrhagic stroke (to distinguish from haemorrhagic transformation of ischaemic stroke): a) intracerebral and b) subarachnoid haemorrhage (reported individually and as a composite) (adjudicated)
  - ii) other intracranial haemorrhage: a) subdural and b) extradural haemorrhage (reported as a composite) (adjudicated)
3. Fatal and non-fatal (reported individually and as a composite) major extracranial haemorrhage: i) upper gastrointestinal; ii) lower gastrointestinal; iii) sight-threatening ocular; iv) multiple trauma; v) other (adjudicated) (42,82)
4. Clinically relevant non-major bleeding (if hospitalised) (adjudicated)
5. Composite outcome of fatal and non-fatal major extracranial haemorrhage and clinically relevant non-major bleeding (if hospitalised)

### 3.3 TERTIARY ENDPOINTS

The following exploratory endpoints will also be studied. These will be time to event except hospitalisations (details in section 9.5.1).

1. Transient ischaemic attack
2. Unplanned hospitalisation
3. Hospitalisation with heart failure
4. New diagnosis of cancer (colorectal/other)
5. Death due to cancer (where cancer is underlying cause of death)
6. CKD progression
7. New diagnosis of dementia
8. Major non-traumatic lower limb amputation

The definitions of clinical endpoints used in ATTACK are detailed in Appendix 1.

### 3.4 ASSESSMENT OF SAFETY

There are four safety endpoints within ATTACK's secondary endpoints: intracranial haemorrhage, major extracranial haemorrhage; composite of intracranial haemorrhage and major extracranial haemorrhage; and clinically relevant non-major bleeding (if hospitalised). CKD progression is included as an exploratory endpoint.

Trial participants will be asked to contact the study team to report bleeding involving the need for hospitalisation and/or transfusion and overt bleeding requiring face-to-face healthcare professional advice. Participating GPs will be asked to log any clinically relevant bleeding episodes (and cardiovascular events) that they become aware of with their Regional Centre.

A standardised approach to the definition of our bleeding endpoints will be followed. It will be recorded whether individual events result in the discontinuation of aspirin (permanent and temporary). Any bleeding event that results in hospitalisation, or occurs as a hospital inpatient, will be formally adjudicated. Safety data will be included in a report produced for the Data Monitoring and Ethics Committee (DMEC), annually or more frequently if requested by the DMEC.

If an eGFR has not been recorded within 15 months of the last one, we will contact the GP practice.

## 4. TRIAL DESIGN

ATTACK is a pragmatic multicentre open label randomised controlled trial. Recruitment is from UK primary care. Whilst there are many important strengths of a placebo-controlled approach, an open label design does offer the advantages of substantially lower trial costs. There is also the possibility of enhanced generalisability and transferability to routine medical care because the treatments more accurately reflect usual clinical practice. It is possible that the choice of an open label design increases the consent rate as potential participants may be reluctant to take placebo and wish to know their allocation (83). Patient compliance may be better in prospective randomised open label blinded endpoint trials than in placebo-controlled studies (84). Assessment of safety will be a particular issue, and it is not possible in an open trial to mitigate the risk that allocation to aspirin will increase the reporting of symptoms. However the impact of knowledge of treatment allocation on outcome measurement will be minimised with blinded independent outcome adjudication of major clinical endpoints, including all bleeding events that require hospitalisation.

A flow diagram of the trial is provided in Appendix 2.

## 5. TRIAL PARTICIPANTS

### 5.1 INCLUSION CRITERIA

1. Males and females aged 18 years and over at the date of screening
2. Subjects with CKD (reduced eGFR and/or albuminuria) defined as:
  - a. estimated glomerular filtration rate [eGFR]  $<60\text{mL}/\text{min}/1.73\text{m}^2$  for at least 90 days, and/or
  - b. kidney disease code on the GP electronic patient AND most recent eGFR in CKD-defining range ( $<60\text{mL}/\text{min}/1.73\text{m}^2$ ), and/or

- c. albuminuria or proteinuria (defined as urine albumin:creatinine ratio [ACR]  $\geq 3\text{mg}/\text{mmol}$ , and/or urine protein:creatinine ratio [PCR]  $\geq 15\text{mg}/\text{mmol}$ , and/or +protein or greater on reagent strip)\*
3. Subjects willing to give permission for their paper and electronic medical records to be accessed and abstracted by trial investigators for the duration of the trial
4. Subjects willing to be contacted and interviewed by trial investigators should the need arise for adverse event assessment
5. Subjects able to communicate well with the investigator or designee, to understand and comply with the requirements of the study and to understand and sign the written informed consent

\* where albuminuria measurements are not available KDIGO state that measurements of urine protein:creatinine ratio or urine protein reagent strips can be substituted. Negative to trace on protein reagent strip is equivalent to ACR  $< 3\text{mg}/\text{mmol}$ ; trace to + is equivalent to ACR  $3\text{--}30\text{mg}/\text{mmol}$  (3). The relationship between reagent strip measures and ACR depends upon urine concentration and in this context for the purposes of ATTACK we are regarding +protein or more as indicative of significant albuminuria. A single abnormal albuminuria/proteinuria test is required for entry to the trial: day-to-day variation in albumin excretion is substantial and the literature linking albuminuria to adverse outcomes is predicated upon single ACR readings; robust cohort data confirm that for urine ACR down to  $1.7\text{mg}/\text{mmol}$  multiple urine samples do not improve performance of CV mortality risk models beyond information achievable by implementation of one ACR value (85).

## 5.2 EXCLUSION CRITERIA

1. Subjects with CKD GFR category 5
2. Subjects with pre-existing CVD: angina, MI, stroke (ischaemic and haemorrhagic [intracerebral/subarachnoid]), TIA, significant peripheral vascular disease, coronary or peripheral revascularisation for atherosclerotic disease; aortic aneurysm is not an exclusion criterion
3. Subjects with a pre-existing condition associated with increased risk of bleeding other than CKD: upper GI bleed or peptic ulcer in the previous five years, lower GI bleed in previous twelve months, active chronic liver disease (such as cirrhosis), bleeding diathesis (investigator opinion)
4. Subjects taking over the counter aspirin continuously
5. Subjects currently prescribed anticoagulant or antiplatelet agent. These include (note this list is subject to change as drugs are withdrawn or developed over the course of the trial):
  - acenocoumarol, phenindione, warfarin
  - apixaban, edoxaban, rivaroxaban
  - argatroban, bivalirudin, dabigatran
  - aspirin, cangrelor, selexipag, cilostazol, clopidogrel, dipyridamole, prasugrel, ticagrelor, abciximab, eptifibatide, tirofiban, epoprostenol, iloprost
  - unfractionated heparin, dalteparin, enoxaparin, tinzaparin danaparoid, fondaparinux
6. Subjects who are currently and regularly taking other drugs with a potentially serious interaction with low-dose aspirin. These include (note this list is subject to change as drugs are withdrawn or developed over the course of the trial)\*:
  - non-steroidal anti-inflammatories (except topical preparations), including: aceclofenac, acemetacin, celecoxib, dexibuprofen, dexketoprofen, diclofenac (and combination diclofenac-misoprostol preparation), etodolac, etoricoxib, felbinac, fenoprofen, flurbiprofen, ibuprofen, indometacin, ketoprofen, ketorolac trometamol, mefenamic acid,

- meloxicam, nabumetone, naproxen (and naproxen-esomeprazol), parecoxib, phenylbutazone, piroxicam, sulindac, tenoxicam, tiaprofenic acid, tolfenamic acid
- nicorandil
7. Subjects with a known allergy to aspirin or definite previous clinically important adverse reaction to aspirin
  8. Subjects with poorly controlled hypertension, defined as latest recorded systolic BP  $\geq 180$ mm Hg and/or diastolic BP  $\geq 105$ mm Hg
  9. Subjects with other conditions which in the opinion of their General Practitioner (GP) would preclude prescription of aspirin in routine clinical practice, for example significant anaemia or thrombocytopenia
  10. Subjects who are pregnant or likely to become pregnant during the study period
  11. Subjects with malignancy that is life-threatening or likely to limit prognosis, other life-threatening co-morbidity, or terminal illness
  12. Subjects whose behaviour or lifestyle would render them less likely to comply with study medication (e.g. alcoholism, substance abuse, debilitating psychiatric conditions or inability to provide informed consent)
  13. Subjects in prison
  14. Subjects currently participating in another clinical trial of an investigational medicinal product or who have taken part in such a trial in the last three months (Covid-19 vaccine studies are acceptable)

\* Concomitant treatment with serotonin selective reuptake inhibitors is not an exclusion criterion. There are data suggesting an increased bleeding risk, but the findings are derived from observational studies and are not consistent (86). Any absolute increase in bleeding risk is likely to be small, and the use of serotonin selective reuptake inhibitors has not been an exclusion in other aspirin trials such as ASPREE and ASCEND.

## 5.3 CONTINGENCY PLAN FOR PARTICIPANT WELL-BEING

### 5.3.1 BEFORE RANDOMISATION

GPs will be provided with a Study Site File outlining trial procedures and will be trained in an initiation visit via online video training. Inclusion and exclusion criteria are based on coded primary care data. Exclusions not captured with disease codes will be assessed by a GP review of the screening list and will be reconfirmed at the consent visit using a checklist of key items. The GP will be consulted where there is remaining doubt or ambiguity, and will ultimately have the decision of who participates in the study.

The training materials will make it clear that the guiding principle is that patients should be excluded where their bleeding risk is above acceptable levels or there are other circumstances such that the GP would not prescribe aspirin to the same patient outside the trial. Previous mild dyspepsia is not an exclusion criterion for the trial. Where GPs are concerned about individual risk to patients they will have the option to order additional safety assessments.

The exclusion of potential participants on the grounds of bleeding diathesis is on the basis of investigator opinion (see Exclusion Criteria Section 5.2). Thrombocytopenia is an important indicator of diathesis. However, the risk of bleeding at any given platelet count is likely to be related to many factors including age, blood pressure, kidney function and, in the case of gastrointestinal bleeding, the presence of *Helicobacter pylori* infection. There are no widely accepted protocols governing the use of aspirin in thrombocytopenia (87), and very limited evidence to guide decision-making. It has

been argued that aspirin can probably be safely continued in patients post cardiac bypass surgery with platelet counts below  $50 \times 10^9/L$ , unless clinical bleeding occurs or the count falls below  $20 \times 10^9/L$  (88); others have recommended ("in the absence of evidence") stopping antiplatelet agents in people with stable coronary artery disease and a platelet count  $<50 \times 10^9/L$  (89). We are therefore not proposing a fixed platelet count below which participants are automatically ineligible. However, any participant in whom the latest platelet count is below  $70 \times 10^9/L$  will be automatically and electronically flagged at the Regional Centre. The Regional Centre will then telephone the patient's GP/SSC to discuss whether they would be willing to prescribe aspirin on this basis, following guidance within the Protocol that "patients should be excluded where their bleeding risk is above acceptable levels such that the GP would not prescribe aspirin to the same patients outside the trial" (Section 5.3.1). We will ask the DMEC to review bleeding risk subdivided by platelet count.

We are not defining a fixed haemoglobin level below which participants are automatically ineligible. Anaemia is not a consistent exclusion criterion in previous aspirin trials. However, any participant in whom the latest haemoglobin is below  $9g/L$  or  $<100g/L$  with  $MCV \leq 75 fL$  will also be flagged at the Regional Centre. The Regional Centre will then telephone the patient's GP/SSC to discuss whether they would be willing to prescribe aspirin to this particular individual based on a holistic assessment of their bleeding risk.

Analysis of initial pilot data ( $n = 2,300$ ) in August 2020 indicate that the numbers of volunteers with previously undiagnosed persistent anaemia or thrombocytopenia picked up at screening according to these definitions is very low ( $<1:1000$  and nil respectively).

### **5.3.2 AFTER RANDOMISATION**

Patient characteristics associated with a higher risk of bleeding are detailed in Sections 1.4 and 1.6.4. All decisions around gastroprotection will be at the discretion of the treating physician.

Trial participants will be advised to seek advice from their usual treating physician for any condition arising during the course of the study. Treating physicians will be asked to follow their usual practice for the management of dyspeptic symptoms or anaemia. Participants who have their study medication stopped by their GP due to side effects of the treatment (e.g. major bleeding) will continue in the trial and be observed for the development of endpoint events.

Treating physicians will be advised to commence participants in the usual care arm on aspirin where an indication arises. The patient's usual physician will be asked to discontinue aspirin therapy when participants in the aspirin arm are commenced on anticoagulation or another antiplatelet agent (except where combination therapy is clinically indicated owing to a qualifying event), or where there is a clinically important reason for a patient to be commenced on any drug with a strong interaction with aspirin. These patients will also continue in the study and be observed for the development of endpoints.

Randomised patients who commence renal replacement therapy will not be withdrawn from trial treatment unless another indication for this arises.

## **5.4 WITHDRAWAL OF PARTICIPANTS FROM THE TRIAL**

Patients may discontinue study treatment as a result of a clinical decision, due to non-compliance with the Protocol, or drug toxicity, but will still be followed up and included in the intention-to-treat

analysis. Subjects will be free to withdraw (defined as the withdrawal of consent for record linkage and the collection of follow-up data) from the trial at any time. The participants will be made aware that this will not affect their future care. Participants will be informed (via the information sheet and consent form) that should they withdraw from the trial, their data collected prior to withdrawal may be used in the final analysis.

## **6. TRIAL PROCEDURES**

### **6.1 INFORMATION TECHNOLOGY**

The information technology (IT) infrastructure to support the trial will be provided by The Computer Room (TCR [Nottingham] Ltd). A bespoke ATTACK software tool (ATTACK toolkit) and management system (ATTACK database) will underpin the trial, and allow a complete set of data collection, administration, reporting and development tools for both the research team and participating practices.

Clinical outcomes will be classified according to standard frameworks (International Classification of Disease [ICD]-10 disease codes and Office of Population Censuses and Surveys [OPCS]-4 procedure codes) linked to structured clinical vocabularies/dictionaries of clinical terms (SNOMED CT, Read version 2 and Read version 3 (CTV3)).

The practice-based ATTACK toolkit in each participating GP practice will enable identical potential patient searches to be performed at every site, and allow for electronic medical record follow-up of patients via Read and SNOMED codes. Adaptations to the trial IT architecture in response to changes in the NHS operating environment (for example any transition from Read codes to SNOMED CT in the primary care electronic record) will be performed according to need.

Computer-held data including the trial database will be held securely and password protected. All data will be stored on a secure dedicated web server within the N3 NHS Private Data Network, to which only authorised study personnel will have access. This is compatible with, and has the relevant security policies in place, to obtain patient-matched hospital admission data and ONS data for consented patients from NHS Digital. Access will be restricted by user identifiers and passwords (encrypted using AES-25S encryption). Information about the trial in the participant's medical records/hospital notes will be treated confidentially in the same way as all other confidential medical information. The storage of this data will comply with all relevant information governance guidelines.

### **6.2 RECRUITMENT**

All trial recruitment will be from UK Primary Care. There will be three geographical recruitment hubs based at Regional Centres in Southampton (South), Nottingham (Midlands) and Middlesbrough (North). Each hub will be supported by a dedicated Trial Coordinator and Principal Investigator (PI). The activities of the hubs will be coordinated and monitored by the Trial Manager based at the University of Nottingham.

GPs will identify eligible patients at their practice using an automated search. The practice will be able to download the ATTACK toolkit required to perform the search from the web. The toolkit will contain query files to perform searches on the GP practice clinical system based on the inclusion and exclusion criteria. The use of pre-existing tests to identify participants, together with virtual



consent and outcome ascertainment from routinely collected GP and hospital data, means that the ATTACK trial is fully Covid-secure. This is of particular importance for a study in the CKD population, because most will be clinically vulnerable, due to their kidney condition and co-morbidities).

These automated searches use a combination of biochemical test results and coded clinical terms. The Read coded prevalence of CKD GFR categories 3 to 5 in England is 4.1% of people aged 18 years and over (87). This is substantially lower than the estimated actual prevalence of 6.1% of people aged 16 and over (88). Unlike CKD G3-5 the coding of CKD GFR categories 1-2 has never been incentivised under the Quality and Outcomes Framework (QOF) and is therefore likely to be far less complete than that for CKD G3-5. Miscoding of CKD is also common: 11% of people with a CKD 3-5 Read code in the National CKD Audit did not have current biochemical evidence of CKD (89). For these reasons numerical values for eGFR and albuminuria/proteinuria rather than clinical terms will be predominantly used to identify potential participants.

The search will return a list of potential patients (as a .csv file), which will be held within the practice. The GPs will check the list of patients to confirm eligibility and are required to provide confirmation that they are happy for the patients to be contacted and screened by signing the search list and documenting any exclusions.

An electronic screening log will be generated based on the final list, and will be updated with any exclusions during the consent process. The following information will be stored in the trial database: screening number, patient initials, year of birth, and encrypted NHS number. The patient's NHS number is required to be able to uniquely identify each patient, should the practice lose their data and require a back-up. It will be encrypted as follows: at the practice, the patient's NHS number will be encrypted automatically by the toolkit prior to being uploaded to the trial database; the unique encryption key, to allow decryption of the NHS number, is the NHS number itself. There is therefore no way that this information can be decrypted outside of the practice. In this instance, the encrypted NHS number is not a strong identifier for the patient.

An automated invitation pack will be sent to the eligible patients via Docmail, a highly secure online mail management system. The pack will include a participant invitation letter, a copy of the Research Ethics Committee (REC)-approved Participant Information Sheet (PIS) and Informed Consent Form (ICF), a reply slip and pre-paid return envelope (addressed to the Regional Centre).

People who respond to express an interest will be contacted, primarily by telephone, to give them further information and allow them to ask questions. Suitable patients will be invited to a consent consultation. Patients who do not respond to the initial invitation may be sent a reminder from their GP practice via letter/email/text message.

### **6.3 INFORMED CONSENT**

All participants will provide written informed consent. The process for obtaining participant informed consent will be in accordance with REC guidance, and Good Clinical Practice (GCP) and any other regulatory requirements that might be introduced. The investigator or their nominee and the participant shall both sign and date the informed consent form (ICF) before the participant can enter the trial or undergo any interventions. In the event that consent is taken remotely, the participant shall sign and date the consent form, and the investigator or nominee will sign and date the

corresponding confirmation of consent process form. Both these forms will be required for full evidence of consent.

The consent will include permission for:

- electronic record linkage via NHS Digital to the ONS for mortality and cancer registration and HES, and
- access by the research team to hospital records where necessary for the purposes of endpoint adjudication, and
- access to their GP records

For this trial, research nurses (or a registered medical professional with suitable study training) will be obtaining informed consent, as delegated by the PI at each Regional Centre. The research nurses will receive considerable training on informed consent, the trial, and the treatment in question, prior to the trial start.

Participants will have received a PIS in advance of their consent consultation (at least 24 hours), allowing them ample time to consider their participation. The research nurse will explain the details of the trial, and will answer any questions that the participant has concerning study participation.

One copy of the ICF will be kept by the participant, one will be kept by the Investigator, and a third will be retained in the site file at the GP practice; practice staff will be asked to scan this into the patients' electronic GP record.

The investigator will inform the participant of any relevant information that becomes available during the course of the study, and will discuss with them whether they wish to continue with the study. If applicable they will be asked to sign revised consent forms. If the ICF is amended during the study, the investigator shall follow all applicable regulatory requirements pertaining to approval of the amended ICF by the REC and use of the amended form (including for ongoing participants). Should there be any subsequent amendment to the final Protocol which might affect participation in the trial, continuing consent will be obtained using an amended consent form which will be signed by the participant.

The decision regarding participation in the study is entirely voluntary. The investigator or their nominee shall emphasise that consent regarding study participation may be withdrawn at any time without penalty or affecting the quality or quantity of their future medical care, or loss of benefits to which the participant is otherwise entitled.

## **6.4 CONSENT CONSULTATION**

At the consent consultation, which may be conducted virtually, patients will be consented by an appropriately trained research nurse or registered medical professional with suitable study training, and inclusion/exclusion criteria will be checked. Height and weight will be recorded (if known by the patient), as well as basic demographic and clinical details, namely self-defined ethnicity, smoking history, and alcohol consumption. All participants will also complete an EQ-5D-5L questionnaire. If the research nurse has any concerns over the eligibility of a patient, they will discuss it with the GP at the practice, who will ultimately decide if the patient is suitable.

Additional information, including postcode (used to generate Index of Multiple Deprivation (IMD)), summary diagnoses, cardiovascular risk factors (for example diabetes [type and duration], hypertension and lipid profile) and concomitant medications will be automatically extracted from the EPR as required.

Patients will be asked to specify their preferred method of communication with the research team (electronic/phone/paper).

The GFR category at entry (using the data from the initial search of GP practices systems before practices mail-out to potential participants) will be determined according to the CKD-EPI eGFR, corrected for ethnicity. For sites where the Modification of Diet in Renal Disease (MDRD) eGFR is reported, CKD-EPI eGFR will be calculated from the standardised serum creatinine.

## **6.5 RANDOMISATION**

Consenting eligible patients will be randomised (open label randomisation) 1:1 via an independent web-based system (TENALEA) using random-block size, to GP prescription of aspirin vs no additional treatment (and avoidance of aspirin), stratified by age, diabetes and CKD severity. Patients and study staff will be aware of the randomisation decision as there is no blinding to treatment allocation.

Participants randomised to receive aspirin will be asked to take prescribed aspirin rather than purchase OTC aspirin to assist in monitoring adherence. The method of prescribing will be at the discretion of the treating physician and is not mandated by the Protocol, but practices will be encouraged to prescribe using a system of Repeat Prescribing (3-month prescriptions), where prescriptions are re-ordered (by patient or pharmacy) in preference to Repeat Dispensing, where prescriptions are issued automatically (typically on a monthly basis). This will also help with tracking adherence to prescribed treatment and may reduce prescription costs. Patients who pay for their prescriptions will be offered reimbursement.

## **6.6 ENDPOINT CAPTURE AND ADJUDICATION**

There is no practice-based follow up. Potential outcomes will be ascertained from multiple data sources:

- ONS for mortality and cancer registration
- HES for hospital admissions
- General practice EPR for coded CVD episodes, bleeding episodes, coded diagnoses of dementia, recorded eGFR, and prescription of aspirin and other relevant medications
- Self-reported information (including that from an annual patient questionnaire)
- Reported by GP or admitting hospital

Trial participants will give consent for record linkage using their personal identifiable details (including NHS number and date of birth) at the screening visit. HES and ONS will be accessed approximately annually via NHS Digital. If practices in Wales are required in the face of lower than expected recruitment rates, GP records will be linked to the Patient Episode Database for Wales (PEDW) from the NHS Wales Informatics Services (NWIS). Record linkage for clinical events in Scotland will be carried out for patients within the trial if needed using national record linkage systems (Information Services Division, NHS National Services Scotland) as in the ALL-HEART trial (90). GP records will be searched and updated as regularly as the extraction system will allow.

Patients will be asked to complete follow-up questionnaires annually, either online, or by their preferred method of contact (paper/electronic). Those who do not agree to being contacted in this way will be followed by HES, ONS and the GP EPR. If required, reminders may be sent.

The four sources of data will be cross-referenced in order to build up a potential event record. Potential CVD and major bleeding events will be formally adjudicated by an Endpoint Adjudication Committee (EAC). Notification of a potential study endpoint will trigger the collection of information for endpoint confirmation and adjudication by the EAC.

Hospital discharge summaries and coding records will serve as the primary information source for the adjudication of potential endpoint events. In the pilot phase of the trial (Section 6.9) the feasibility, value and costs of obtaining specific additional information from the original hospitalisation such as electrocardiogram (ECG), imaging and laboratory results to support diagnoses made from coding records and electronic discharge summaries will be explored. Where necessary, the Clinical Research Network (CRN) system will be used to liaise with research nurses in each NHS Trust to directly access hospital test results and, if required, hard copy discharge summaries. The consent process will include permission for the participants' data to be accessed in this way. If there is good agreement, or it proves unfeasible to access source data on a significant scale, the data collection will be streamlined for the remainder of the trial. All emergency admissions will be captured from HES and all new diagnoses of colorectal and other cancer from ONS.

Community strokes are relatively common (35% of the total in OXVASC (91)). Where there is evidence that a patient may have had a stroke and this is not associated with a stroke HES code in the preceding 60 days (for example new GP coded stroke event, patient-reported stroke) the trial team will attempt to obtain copies of any relevant clinical letters from hospital stroke team/neurology that are held on the EPR.

Cardiovascular events are generally well-coded within HES, but the identification of major bleeding will be more challenging. As non-elective blood transfusions are not generally coded within HES, the ATTACK annual questionnaire will include a specific question regarding transfusion.

It is also recognised that many patients with ocular bleeds are not admitted to hospital. GP codes strongly suggestive of sight-threatening eye bleeds will be used to identify possible events; the endpoint adjudication coordinator will obtain and redact additional information from the GP for the committee to review. The annual questionnaire also includes a specific question regarding eye bleeds.

There are three adjudication committees, one for cardiovascular endpoints, one for stroke, and one for major bleeding. The CVD and stroke EAC are chaired by a cardiologist and stroke physician respectively. A key aim of our cardiovascular adjudication process is to distinguish genuine atherothrombotic events from those unlikely to be modified by aspirin (e.g. an episode of atrial fibrillation accompanied by a small troponin rise). The bleeding committee will be chaired by a gastroenterologist. The EACs will meet as frequently as is required to review all potential events. Assuming a positive predictive value of 66%, around 3000 cardiovascular events will require adjudication; the number of bleeding events is likely to be substantially smaller (Table 1). A consensus adjudication model will be followed, whereby two reviewers discuss the cases and reach agreement. In the rare cases that agreement is not reached the case will be discussed with the

Chair to determine the final adjudicated outcome. The adjudication process will run in parallel to systems for safety assessment.

## **6.7 DURATION OF THE TRIAL**

The trial will continue until at least 1,827 adjudicated primary endpoint events (major vascular events) have occurred, or before if the trial is discontinued after the internal pilot (Section 6.9) or for any other reason. It is anticipated that at least 6 years of recruitment (taking account a recruitment pause for the Covid-19 pandemic) and 2.5 years of follow-up will be required to complete the trial.

## **6.8 STOPPING RULES AND DISCONTINUATION**

### **6.8.1 TRIAL STOPPING RULES**

The trial will begin with an internal pilot lasting for 24 months (Section 6.10). The pilot will provide key early data on recruitment and safety to inform the funders and Sponsor of the trial whether to continue, amend procedures or stop the study.

Existing trial data indicate an absolute rate of major bleeding in people with CKD taking aspirin for primary prevention of 0.4% per annum with a relative risk vs. controls of 1.98 (95% CI 1.11-3.52) (n=4,469) (71). A Cochrane review reported that the use of antiplatelet agents in people with CKD (any indication) conferred an increased relative risk of major bleeding of 1.33 (95% CI 1.10-1.65) (27 studies). The relative risks of major bleeding due to aspirin are similar to those in people without CKD, although the absolute risks are higher due to the higher baseline risks in the CKD control groups (53).

Safety will be assessed throughout the trial, both in the pilot phase and after. The DMEC will formally review safety:

- at 27 months (at the completion of the pilot phase [9 months setup, 15 months recruitment] plus 3 months for report writing) using non-adjudicated data
- at 36 months (9 months set up, 24 months recruitment, 3 months for report writing) using non-adjudicated data
- at 45 months (9 months set up, 27 months recruitment, 9 months for adjudication and report writing) using adjudicated data
- annually thereafter (or more frequently if specified by the DMEC) using adjudicated data

The time points for the pilot phase and safety reviews may change, but only with the agreement of the funder. Reasons for this may include if, for example, the setup phase is longer than anticipated, or there are other major contextual events that influence trial recruitment and/or progress.

The absolute and relative risks of major bleeding will be examined by the DMEC and compared with those expected from the literature. All-cause mortality and the primary event rate will also be studied in order to determine net benefit, i.e. benefits minus harms.

Aspirin use requires a consideration of the balance of risk vs. benefit in all populations. The DMEC will recommend termination of the trial if, in their view:

- the randomised comparisons provided have proven beyond reasonable doubt that the level of harm is unacceptable, or
- the use of aspirin is clearly contraindicated (or clearly indicated) in terms of the net effects.

This follows the approach adopted by the ASCEND investigators (92).

Clinical judgement will be required in interpreting these analyses and reaching a recommendation. The DMEC will consider whether the evidence meets standards for treatment recommendations and practice guidelines, mindful that less evidence should be required to stop the trial for harm than benefit given the primacy of patient safety (93). The absolute number of major bleeding events during ATTACK is likely to be low (estimated n=16 in aspirin-treated and n=8 in controls during the pilot phase), and therefore that the confidence levels around any estimates of absolute and relative risk will be initially wide but narrow throughout the course of the trial. Hazard ratios may be unstable and drift over time into marginal levels of significance. Multiple “looks” at the data may give rise to a transient “signal” of benefit or harm (94). Therefore criteria of proof beyond reasonable doubt cannot be specified precisely, but in general a difference of at least three standard deviations in an interim analysis of a major endpoint would be needed to justify halting, or modifying, such a study prematurely, especially for a comparison based on relatively few events (<100) (92).

If the DMEC have concerns that fall short of “beyond reasonable doubt” on the basis of the early unadjudicated data they will also have the option to halt the trial pending a process of formal adjudication.

There are other instances where the DMEC may consider it advisable to advise termination of the study:

- flaws in design or conduct of the study come to light
- external new information on the treatment comes to light
- resources are inadequate to complete the trial

If the trial is prematurely terminated or discontinued, the Chief Investigators will immediately notify the Sponsor and Regional Centre Principal Investigators. After notification, the Principal Investigators will contact all participants within 90 days, all trial materials will be collected in the Trial Master File and all data will be completed to the greatest extent possible.

## **6.8.2 INDIVIDUAL PARTICIPANT TREATMENT STOPPING CRITERIA**

GPs should follow their usual practice for the management of dyspeptic symptoms or anaemia in trial patients

In patients randomised to receive low-dose aspirin, aspirin should be discontinued in the following circumstances:

- diagnosis of a non-traumatic major bleed
- commencement of treatment with warfarin, aspirin or other anti-thrombotic drug (except where continuation of aspirin is clinically indicated owing to a qualifying event)
- where there is a clinically important reason for a patient to be commenced on any drug with a strong interaction with aspirin

GP should exercise their clinical judgement as to whether aspirin is discontinued (permanently or temporarily) under any other circumstances. For subjects undergoing elective procedures GPs (and other treating doctors) should follow the practice they would for any other patient taking aspirin

Patients in the usual care arm should be commenced on aspirin where an indication arises.

## 6.9 PILOT PHASE

The first 24 months of the study (covering an estimated 9 months set up followed by 15 months recruitment) were planned as a pilot, but the timings and details of the pilot phase have been modified in light of the Covid-19 pandemic.

The key objective of the pilot is to assess GP and patient recruitment. Additional objectives are to:

- finalise major event assessment procedures
- monitor safety
- assess fidelity to allocated group and patient withdrawal rates

Pilot data will be analysed from the end of month 24 and reported by the end of month 27 of the study. The non-adjudicated primary event rate in the control arm after 24 months of recruitment (33 months of study) will be assessed by the DMEC only (who may in turn raise concerns to the TSC).

### 6.9.1 PILOT STUDY AT 24 MONTHS

**Assessment of practice and patient recruitment.** We will report on the number of practices overall, and by area, that: indicate willingness to take part; perform eligibility assessment; and start patient recruitment. The number (and percent per list size) of eligible patients per practice and the number and percentage of eligible patients willing to participate, entering the run-in phase and commencing the trial will be recorded. The aim over 3.5 years is to recruit 25,210 patients, with approximately 8,000 patients in the first 15 months of recruitment for the pilot phase. At the end of the pilot phase, traffic light criteria will be used establish whether: the trial should continue without modification (green); study recruitment strategy changes are required (amber); or the trial should discontinue (red). The red option is driven by a recruitment rate under 60% of target. If patient recruitment is below estimated further practices will be recruited into the trial (Table 4).

Test searches at practices participating in the *Helicobacter* Eradication Aspirin Trial (HEAT) (95), indicated an average of 370 potentially eligible patients per practice. A rate of randomisation of 15% would give 55 participants per practice. With a more pessimistic set of assumptions the trial remains feasible. The prevalence of CKD 1-5 is in the order of 12% from population data. The National Diabetes Audit highlighted that there are over 1 million people with diabetes and CKD 1-2 (96). Not all of these patients will have blood and urine tests that are diagnostic of CKD on their GP records, but if 8% of adults can be diagnosed with CKD 1-5 on the basis of test results, and of these 70% have no pre-existing CVD, and 80% of these are not taking aspirin, then a typical practice will include around 300 eligible patients. The inclusion of a run-in phase to improve treatment adherence may reduce the proportion of invited patients who are randomised. If the rate of randomisation is 8%, full recruitment will be possible from the network of 1,200 practices participating in HEAT (1,257 enrolled, 1,163 active [96% in England]) (97), with whom the ATTACK investigators have existing links through a common trial management team. If the number of eligible patients and/or the consent rate was lower still there is nonetheless the ability to recruit additional practices outside the HEAT network: overall 48% of general practices across England take part in NIHR CRN Portfolio studies (98). As in HEAT there is also scope to extend into Scotland, Wales and Northern Ireland

Table 4. Recruitment targets during internal pilot

	Number of practices	Patients recruited per practice	Total patients recruited	Action
<b>Green</b>	≥160	≥50	≥8,000	Continue trial without modification
	≥200	≥40		
	≥229	≥35		
	≥267	≥30		
	≥320	≥25		
	≥400	≥20		
<b>Amber</b>	A combination of a sufficient number of practices and patients to recruit at least 4,800 patients but insufficient to recruit 8,000 patients		4,800-8,000	Apply recruitment strategy changes
<b>Red</b>	<96	<50	<4,800	Stop trial
	<120	<40		
	<137	<35		
	<160	<30		
	<192	<25		
	<240	<20		

**Major cardiovascular event assessment.** The CVD adjudication team will be recruited in the early stages of the trial and the adjudication process honed during the pilot phase. Hospital discharge summaries will serve as the primary source of potential endpoint events. These will be assessed and categorised into: i) clear major event or no event; or ii) more information required. In the latter situation the feasibility, value and costs will be explored of obtaining specific additional information from the original hospitalisation such as ECGs, CT scan results, photocopied medical notes to assess symptoms and post mortem results if in-hospital death. Events that are uncertain will be reassessed using whatever additional information can be obtained. The results will clarify the extent of data collation the Regional Centres will need to undertake post-pilot and how to best organise the adjudication teams cost effectively. Information on deaths in trial participants will be obtained from the ONS after 9 months of recruitment. For those certified as CVD in the community without hospitalisation the availability of data from GPs and post mortem will be specifically examined.

The pilot report will also report information on:

- safety from any bleeding events requiring hospitalisation in both arms using HES data (non-adjudicated) and other information sources (for example, patient questionnaires), and any other serious adverse events
- fidelity to allocated group by examining repeat prescribing data from GP systems. Where scripts are issued by Repeat Prescribing the electronic record will record whether prescriptions have been requested by the patient or pharmacy (although it will not be possible to determine whether they have been collected). We intend to explore this after six months and twelve months. If the results indicate a high proportion of aspirin-allocated subjects are not collecting aspirin prescriptions we will review the run-in process described in Section 6.5.



This information on adherence will be supplemented by questions on the annual patient questionnaire related to taking medication

- whether patients on usual care had taken OTC aspirin from follow-up questionnaires in those reaching 12 months after recruitment
- withdrawal as the number (%) of patients who withdraw from the study and refuse access to linked routine data

### **6.9.2 ASSESSMENT OF EVENT RATE**

A report to the DMEC on adjudicated major CVD events and bleeding events (by arm) will be issued 45 months into the study based on 27 months of actual recruitment (estimated 23% of primary endpoint events, 226 in the control arm).

Data on adjudicated major CVD events and bleeding events (overall, not by arm) will be reviewed by the TSC at its regular meetings. The TSC will have the option of increasing the sample size or prolonging the scheduled treatment period if the event rate is substantially lower than anticipated.

## **7. TRIAL TREATMENT**

### **7.1 DETAILS OF INVESTIGATIONAL MEDICINAL PRODUCT**

#### **7.1.1 DESCRIPTION**

Active treatment will be aspirin (CAS 50-78-2) 75mg given once daily. Non-enteric coated tablets or dispersible preparations may be used interchangeably. Control subjects will receive no additional treatment to their usual medication.

Aspirin will be prescribed using the standard NHS prescribing system which is automatically logged in the GP practice electronic system. Standard labelling and packaging will be used. There is no placebo in this study; aspirin will be compared to no additional therapy.

Aspirin exerts an antiplatelet action through the irreversible inhibition of cyclooxygenase-1. This prevents the generation of prostaglandins, including thromboxane A<sub>2</sub>, and endothelial prostacyclin. Thromboxane A<sub>2</sub> is an inducer of platelet aggregation and prostacyclin an inhibitor of platelet aggregation. As aspirin is less effective at reducing prostacyclin production than thromboxane A<sub>2</sub> generation, the net effect favours reduced platelet aggregation and less thrombus formation (99). 75mg is the lowest proven effective antiplatelet dose of aspirin (16). Equivalent doses of the enteric-coated aspirin are not as effective as plain aspirin (100). No clear clinical benefits in terms of reduction of GI bleeding or ulceration with enteric coating have been demonstrated (101).

#### **7.1.2 MANUFACTURE/MARKETING AUTHORISATION**

There are several different manufacturers of generic aspirin in the UK. Because the aspirin will be prescribed using the standard NHS prescribing system, any of the available preparations may be used within the study.

#### **7.1.3 STORAGE**

Standard storage conditions apply.

#### **7.1.4 KNOWN SIDE EFFECTS**

Full details of aspirin side effects, including drug interactions, are provided in the Summary of Product Characteristics.

#### **7.1.5 MANAGEMENT OF STUDY DRUG OVERDOSE**

This will be in accordance with the recommendations of the Summary of Product Characteristics.

### **7.2 CONCOMITANT AND RESCUE MEDICATIONS AND TREATMENTS**

There is no concomitant or rescue medication mandated in the Protocol. GPs may prescribe gastroprotection in those patients randomised to aspirin who are felt to be at the greatest risk of bleeding (Sections 1.4 and 1.6.4), but these decisions will be at the discretion of the GP.

### **7.3 ADHERENCE TO PRESCRIBED TREATMENT**

An analysis of aspirin primary prevention trials reported persistence rates (proportions still taking trial medications/not withdrawing from trial treatments) that varied between 50 and 90% over 3 to 5 years (102), with an average persistence across the six studies of 73% at 4.5 years, very similar to the figure of 13,012/19,114 seen at 5 years in the Aspirin to Reduce Events in the Elderly (ASPREE) trial (103).

In ASPREE 2-3% of participants came off study medications for the purpose of going on open-label aspirin (103). Incomplete adherence in the aspirin arm will also dilute the treatment effect measured by ITT, reducing the relative risk towards the null. However, the estimated risk reduction in ATTACK is conservative and has been carefully considered in the light of other aspirin trials analysed using ITT. This effect has therefore already been factored into our sample size estimations. As near-complete routine outcome follow-up data will be available, the threat to internal validity as a result of different withdrawal rates between the two arms will be minimal.

Self-reported compliance with prescribed aspirin and OTC aspirin consumption in the usual practice arm will be assessed in the annual ATTACK questionnaire. Treatment adherence will also be assessed from routine downloads of GP prescribing data.

Where poor adherence is demonstrated the project team will intervene pro-actively to try and address the issue. The Regional Centres will play a key role in these processes. During the setup phase we will include a dedicated session on the importance of adherence in our staff training that will include discussion of strategies to re-engage patients. Where needed, research staff may attempt to contact patients directly to discuss and emphasise the importance of taking the study medication.

### **7.4 URGENT SAFETY MEASURES**

In the event of a situation requiring an Urgent Safety Measure (USM), immediate action will be taken to manage the event and protect the participant(s). It is the responsibility of the Chief Investigators to take appropriate action to protect study participants from any immediate hazard to their health and safety, and to notify the Sponsor of any safety concerns as well as any USM implemented. The Sponsor can also implement an USM. Should the Chief Investigators not be available the responsibility to introduce and report any USM will pass to the PI at the relevant Regional Centre.

The Sponsor will ensure that any necessary USM are being implemented, that the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA) REC have been notified within the specified timelines and that hosting organisations are aware of the need to implement USM. It is the responsibility of the research team to notify the CIs/PIs immediately after they have become aware of any issues that may put health and safety of participants at risk.

Should an urgent safety issue be identified the Sponsor or Investigator will contact the MHRA within 24 hours of identifying the safety issue. The Sponsor or Investigator will also notify the HRA REC (the REC which issued the favourable ethical opinion) immediately by phone and in writing within 3 days. These communications will be followed up by a written notification from the Sponsor or Investigator within three days of the incident. The notification should be in the form of a substantial amendment and should describe the event, the measures taken and justification for the measures taken.

Examples of situations requiring urgent safety measures might include:

- an increase in the frequency of Serious Adverse Events (SAEs) which is deemed clinically important
- a new event or information relating to the Investigational Medicinal Product (IMP) that could affect patient safety. This is exceptionally unlikely in the case of aspirin which has been widely taken by patients for many decades.

## 8. TRIAL MANAGEMENT

The **Sponsor** of the trial will be the University of Southampton. The trial will be managed from a central **Trial Coordinating Centre** based at the University of Nottingham, with a designated **Trial Manager**. The activities of the Trial Coordinating Centre will be agreed and documented in the Task Allocation Matrix for the trial, and will include but not be limited to: communication with the CRN, liaison with potential centres, trial set-up and permissions, recruitment, central coordination, and management and monitoring of trial documents and patient data.

A **Trial Management Group** (TMG), led by the two **Chief Investigators**, will meet regularly to discuss the design and progress of the trial. Patients will be represented on this group and advice will be sought by TMG on relevant decisions from local patient and public involvement bodies.

The Chief Investigators will have overall responsibility for the trial and shall oversee all study management. **Regional Centres** will coordinate the study sites in their area, led by a regional **Principal Investigator**. Regional centres will be responsible for recruiting and liaising with local study sites. A **Study Site** will be a participating general practice. Each practice will have at least one **Study Site Coordinator** (SSC) who will be a primary care physician. The SSC will be responsible for selecting suitable patients from the general practice population. There will be three **Endpoint Adjudication Committees** who will each independently adjudicate possible cardiovascular endpoints, stroke endpoints and bleeding events.

The Southampton **Clinical Trials Unit** (SCTU) will support all statistical processes, including ongoing central statistical monitoring and preparation of open and closed trial reports, randomisation design, set-up, and support.

A **Trial Steering Committee (TSC)** will provide overall supervision on behalf of the Sponsor and Funder and ensure that the project is conducted to the rigorous standards set out in the Department of Health's Research Governance Framework for Health and Social Care and the Guidelines for Good Clinical Practice. The TSC will:

- provide advice, through its Chair, to the Funder, Sponsor, Chief Investigators, Host Institution and Contractor on all appropriate aspects
- concentrate on progress of the trial, adherence to the Protocol, patient safety and the consideration of new information of relevance to the research question
- emphasise that the rights, safety and well-being of the participants are the most important considerations and should prevail over the interests of science and society
- ensure appropriate ethical and other approvals are obtained in line with the project plan
- agree proposals for substantial protocol amendments and provide advice to the sponsor and funder regarding approvals of such amendments
- provide advice to the investigators on all aspects of the trial/project

The TSC will include an independent Chair, a statistician with clinical trials expertise, two clinicians with expertise in the clinical area, a Health Economist, the Trial Manager, the Chief Investigators (one of which will attend each meeting) and two lay members. A representative from the Sponsor will act as an observer. All TSC meetings will have a minimum of 75% majority of independent members. The minimum quoracy for a meeting to conduct business will be 67% of appointed members. TSC meetings will be held at the start of the study and then at least annually thereafter.

The meeting schedule of the TSC will be aligned with that of the **Data Monitoring and Ethics Committee (DMEC)**. The DMEC is the only body involved in the trial with access to the unblinded comparative data. Its role is to monitor these data and make recommendations to the TSC on whether there are any ethical or safety reasons why the trial should not continue, ensuring that the safety, rights and well-being of the trial participants are paramount. The DMEC may be asked by the TSC, Sponsor or Funder to consider data emerging from other related studies.

The DMEC will comprise an independent Chair, a statistician and at least one clinician with expertise in the relevant clinical area. All members will be independent. The Trial Management Team will provide a safety report to the DMEC at a frequency (at least annual) specified by the DMEC. We will obtain contemporaneous safety data from regular searches of the GP EPR for new coded bleeding (and cardiovascular) episodes and from event reporting by Study Site Coordinators to the Regional Centres, and obtain HES data on hospital admissions. The DMEC may wish to meet on a regular basis but will be required, at a minimum, to meet at the following defined time points:

- once the pilot study has been completed to review safety and assess study recruitment and feasibility criteria of the pilot phase of the trial (27 months from the start of the trial)
- 36 months from the start of the trial to assess safety, recruitment and the control event rate
- 45 months from the start of the trial to assess safety, study recruitment and the control event rate

The time points for safety reviews may change if, for example, the setup phase is longer than anticipated, or there are other major contextual events that influence trial recruitment and/or progress.

The Trial Coordinating Centre will undertake monitoring of Regional Centres, focussing on quality assurance, data integrity, adherence to the protocol and checking training. The Sponsor will undertake proportionate monitoring of the processes of the Trial Coordinating Centre, Regional Centres and SCTU.

## **9. STATISTICS**

### **9.1 SAMPLE SIZE**

A total of 25,210 patients (12,605 per arm) will be required in order for the required 1,827 major vascular events to be observed.

#### **9.1.1 INITIAL SAMPLE SIZE ESTIMATE (NOT ACCOUNTING FOR COMPETING RISKS)**

An initial sample size was calculated using NQuery v4.0 assuming a 2% annual usual care event rate and powered to detect a HR of 0.868 for the risk of experiencing a major vascular event with aspirin (proportion event-free at 5-years: 90.4% (usual care) vs. 91.6% (aspirin)). With 85% power, 5% two-sided alpha, 3.5 years for recruitment, 2.5 years follow-up and 1% dropout (withdrawal of consent for follow-up), a total of 1,792 major vascular events would be required overall.

#### **9.1.2 DEFINITIVE SAMPLE SIZE ESTIMATE (ACCOUNTING FOR COMPETING RISKS)**

As the primary outcome measure involves competing risks (deaths from other causes, including deaths from fatal bleeding which are anticipated to be higher in the aspirin arm), a sample size adjustment calculated using the Cumulative Incidence approach is required as recommended by Pintilie and Tai (104,105). Methods to calculate the sample size in the presence of competing risks (104,105) were used under the following assumptions:

- proportional hazards assumption holds between the two arms
- a 2% annual major vascular event rate in the usual care arm
- an initial HR of 0.868 (equivalent to a 1.74% annual major vascular event rate in the aspirin arm)
- a 1.8% annual event rate in the usual care arm for deaths from other causes (including fatal bleeding)
- a 1.85% annual event rate in the aspirin arm for deaths from other causes (including fatal bleeding) i.e. assuming that patients in the aspirin arm will experience a 0.05% annual rate increase of fatal bleeding compared to patients in the usual care arm
- 85% power
- 5% two-sided alpha
- 1% dropout rate
- 1:1 usual care: aspirin arm allocation
- 3.5 year recruitment period
- 2.5 year follow-up period

The corresponding sample size information was calculated as follows (all values rounded to 4 decimal places):

- cumulative incidence at 5 years (in the presence of competing risks) for the usual care arm of 0.0911
- cumulative incidence at 5 years (in the presence of competing risks) for the aspirin arm of 0.0796

- subdistribution HR of 0.8692
- proportion of main event failures in the usual care arm of 0.0782
- proportion of main event failures in the aspirin arm of 0.0682
- pooled proportion of main event failures of 0.0732
- number of major vascular events required of 1,827
- number of patients required (prior to an allowance of dropout) of 24,958
- number of patients required (after an allowance of dropout) of 25,210 (12,605 per arm)


## 9.2 ESTIMATION OF EFFECT SIZE

An initial HR of 0.868 (12.5% RR reduction at five years) is both clinically important and appropriate for the ATTACK study population. This estimate is based upon: current knowledge on the use of aspirin for primary and secondary prevention; the risk profile of people with CKD; and the results observed in the subgroup of participants in the HOT study who had CKD.

Aspirin reduces major vascular events by more than 20% in patients with pre-existing CVD and other groups regarded to be at an annual risk of a major vascular event of more than 3% (16). By contrast in primary prevention, where the annual risk of vascular events is far lower, risk reductions of 10-12% are observed (17–19).

Cardiovascular risk is significantly increased in patients with CKD. It has been argued that CKD should be added to the list of criteria defining people at highest risk of future coronary events (106). The implication that the relative as well as the absolute benefits of aspirin in the primary prevention of major vascular events may be greater in high-risk individuals with CKD is supported by interventional data of aspirin use in this setting from the HOT study, where major cardiovascular events were reduced by 9%, 15% and 66% in those with a baseline eGFR of >60, 45-59 and <45mL/min/1.73m<sup>2</sup> respectively (58). The relationship between observed effect size and eGFR from this post-hoc analysis is shown in Figure 3. In this context we believe a risk reduction of 12.5% in a CKD population to be conservative.

**Figure 3. The effects of aspirin on major cardiovascular events in the subgroup below each cutoff value of GFR (58)**



Reproduced from Jardine MJ et al. *J Am Coll Cardiol* 2010;56(12):956–65.

### 9.3 ESTIMATION OF EVENT RATE

A summary of the findings from the trials considered when deriving an estimate of the control event rate in ATTACK, together with event rate data from additional CKD cohorts/populations and non-renal cardiovascular trials is presented in Table 5:

Table 5. Summary of annual event rates from CKD and CVD cohorts and trials from 1991-2017 ordered by year published

<b>Trial</b>	<b>Year published</b>	<b>Age</b>	<b>Study population</b>	<b>Annual event rate</b>
<b>Systolic Hypertension in the Elderly Program (SHEP) (107)</b>	1991	Mean 73	Historical trial population with hypertension 1% history of stroke 5% history of MI	2.7% non-fatal stroke/MI + CV death in controls
<b>Systolic Hypertension in Europe (SYS-EUR) Trial (108)</b>	1997	Mean 70	Historical trial population with hypertension 4% history of stroke 11% history of MI	3.4% fatal + non-fatal CV disease and stroke (includes heart failure) in controls 2.5% excluding heart failure
<b>Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (109)</b>	2002	Mean 67	Historical high risk hypertensive trial population 23% with history of stroke or MI 13% with history of coronary revascularisation	1.9% non-fatal MI + fatal coronary heart disease
<b>The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial (110)</b>	2007	Mean 62	Contemporary trial population of higher risk type 2 diabetes 33% with pre-existing CVD Mean eGFR 92 and mean ACR 1.4	2.1% non-fatal stroke/MI + CV death
<b>Cardiovascular Health Study (111)</b>	2008 (but historical cohort)	65+	Cohort aged 65+ with CKD No diabetes or previous MI	1.5% CV death
<b>Study of Heart and Renal Protection (SHARP) Trial (77)</b>	2011	Mean 62	Contemporary high risk but relatively young CKD primary prevention trial population	1.8% non-fatal stroke/MI + CV death in controls
<b>Alberta CKD cohort (106)</b>	2012	Mean 72	Contemporary non-selective CKD cohort without diabetes and without previous MI 74% eGFR 44-59 80% no proteinuria	Rate of patients admitted to hospital for MI 0.7% Excludes patients at higher risk due to diabetes and CKD Excludes as outcomes any stroke and community deaths
<b>Alberta CKD cohort population aged 50+ (112)</b>	2014	50+	Contemporary unselected CKD cohort	1.7% coronary death or non-fatal MI Excludes stroke
<b>Alberta CKD cohort population aged 50+ (112)</b>	2014	50+	Contemporary unselected CKD cohort without diabetes and without previous MI	1.3% coronary death or non-fatal MI Excludes stroke
<b>Systolic Blood Pressure Intervention Trial (SPRINT) (113)</b>	2015	Mean 68	Contemporary trial population of people at increased CV risk but without diabetes 17% with clinical CVD 28% with CKD	1.5% fatal + non-fatal MI/stroke

<b>Renal Risk in Derby (RRID) Cohort (78,79)</b>	2017	Mean 72	Contemporary selected primary care cohort	0.77% CV mortality in those without pre-existing CVD
<b>National CKD Audit (114)</b>	2017	Mean 72	Contemporary unselected primary care CKD cohort (England and Wales)	1.8% from HES data (acute MI + acute cerebral infarction + other acute CV disease + stroke non-specified) for elective and emergency admissions Excludes community deaths
<b>A Study of Cardiovascular Events in Diabetes (ASCEND) (42)</b>	2018	Mean 63	Contemporary primary prevention trial population with diabetes (12% eGFR <60mL/min/1.73m <sup>2</sup> , 13% with ACR ≥3mg/mmol)	1.3% non-fatal MI + non-fatal stroke or TIA + vascular death (excluding confirmed cerebral haemorrhage)
<b>Aspirin in Reducing Events in the Elderly (ASPREE) (45)</b>	2018	Median 74	Contemporary primary prevention trial population of healthy elderly (19% eGFR <60mL/min/1.73m <sup>2</sup> )	0.88% fatal coronary heart disease (excluding death from heart failure) + non-fatal MI + fatal or non-fatal stroke
<b>A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE) (47)</b>	2018	Mean 64	Contemporary primary prevention trial population at moderate risk (severe renal disease excluded)	0.90% MI + stroke + CV death + unstable angina + TIA

It is not possible to predict the control event rate for this trial with certainty. The findings of the SHARP trial have been an important influence on the risk of vascular events anticipated in ATTACK. Based upon extrapolation from epidemiological data, the investigators in the SHARP trial estimated an annual rate of major vascular events of 3% in pre-dialysis patients attending nephrology clinics. Definite previous MI or coronary revascularisation were exclusion criteria. The final SHARP study population included 23% with diabetes and 15% with pre-existing vascular disease (angina, stroke or peripheral vascular disease). The mean age was 62 years. In those not on dialysis, the mean eGFR was 27mL/min/1.73m<sup>2</sup>; 36% had CKD GFR category 3 and 43% category 4; the ACR was less than 3mg/mmol in 20%, 3-30mg/mmol in 38% and >30 in 42%.

Overall 13.4% of control group in SHARP experienced a major vascular event in a mean of 4.9 years follow-up. For patients with CKD GFR category 3 and 4 these figures were 10.4% and 12.7% respectively. Excluding revascularisation the control annual event rate was 1.8% overall. Major vascular events were more common where there was proteinuria: for ACR 3-30mg/mmol and >30mg/mmol they were seen in 11.9% and 13.8% respectively of controls, and 9.0% and 10.2% of the intervention subjects (77). These findings are consistent with those from HOT where hypertensive participants with eGFR 30-44mL/min/1.73m<sup>2</sup> experienced a five-year major cardiovascular event rate of 15.5% (58).

In extrapolating these findings to ATTACK, the following factors have been considered: i) the mean eGFR of the primary care CKD population in ATTACK will be higher than that in SHARP, with large numbers in CKD GFR category 3, lowering the anticipated event rate; ii) the primary endpoint in ATTACK excludes revascularisation which will also reduce the number of events; iii) compared with SHARP, the primary care population of ATTACK are likely to be older (for example the mean age of the CKD GFR category 3 to 5 population in the Quality Improvement in CKD Trial (n=23,311) was 75 years (115)).



Age is a strong predictor of vascular events: in the Oxford Vascular Study 75% of coronary vascular events occurred in the 14% of people age over 65 and 54% in the 6% aged over 75 (116). In the Systolic Hypertension in the Elderly Program (SHEP), the annual event rate of major vascular events (fatal- or non-fatal stroke, non-fatal MI or CV death) was 2.7% in the control group (five-year average systolic blood pressure of 155mmHg) and 1.9% of the intervention group (five year average 143mmHg); the mean age of the study population was 73 years, with 5%, 1.5% and 10% with a pre-existing history of MI, stroke and diabetes respectively. Importantly, less than 1% had a history of “renal dysfunction” (107). In the Sys-Eur study, an annual event rate (fatal and non-fatal CVD, including heart failure) of 3.4% and 2.3% was seen in the control and intervention arms of a population of mean age 70 years where 30% had pre-existing “cardiovascular complication” (4% stroke, 11% MI) (108).

The observed rate of major vascular events in a given trial population is however likely to be lower now than it would have been 10-20 years ago. More contemporary CKD cohorts also offer important insights. The annual cardiovascular mortality in those without pre-existing CVD in the contemporary Renal Risk in Derby (RRID) primary care cohort was 0.77% (78,79) with an implied event rate of 2.3% assuming non-fatal:fatal cardiovascular events of 1.8:1 (77). The RRID participants had a mean age of 72 and a mean eGFR of 52mL/min/1.73m<sup>2</sup>; only 16% had albuminuria. In the Alberta CKD cohort the rate of coronary death or non-fatal MI (i.e. excluding stroke) was 1.3% in an older (age ≥50 years) but lower risk CKD population without either diabetes or pre-existing coronary heart disease (112)

ATTACK is a pragmatic study and the estimated event rate of 2% assumes that the trial participants will be rather more representative of the real-world CKD population than a very highly selected group of younger and fitter patients that one might expect to see in a more demanding placebo-controlled study involving multiple visits and additional tests.

As the event rate will be highly dependent upon the age and CKD severity of patients recruited, the age distribution and CKD stage of participants will be closely monitored during the first phase of the pilot in advance of the formal estimation of the control event rate which will take place during the second phase. This will allow time to titrate the number of practices according to the recruitment rate per practice and top up our practice numbers in anticipation of a lower event rate, and to focus recruitment on more severe CKD, thereby enriching the ATTACK population with people at higher risk, should the trial population be younger than expected.

Advice will be sought from TSC should the event rate differ significantly from that anticipated. Table 6 presents alternative scenarios based upon event rates of 2%, 1.8% and 1.6%, and the effects of mitigating the effect of a lower event rate on sample size by accepting a lower power of 80%. ATTACK is powered to detect a modest risk reduction of only 12.5%. A power of 80% has been employed in, for example, the ALL-HEART study (to detect a much larger risk reduction of 20%) (90) and the major HOPE-3 trial (to detect a risk reduction of 22.5%) (117):

Table 6. Sample size and statistical power for ATTACK based upon annual event rate of 2.0%, 1.8% and 1.6%

Control event rate	Initial HR*	Proportion event free at 5-years [Usual Care]	Proportion event free at 5-years [Aspirin]	Alpha (2-sided)	Power	Total number of events required <sup>1</sup>	Number of patients required <sup>1</sup>
2.00%	0.868	90.4%	91.6%	5%	85%	1,827	25,210
2.00%	0.868	90.4%	91.6%	5%	80%	1,597	22,036
1.80%	0.868	91.3%	92.4%	5%	85%	1,823	27,838
1.80%	0.868	91.3%	92.4%	5%	80%	1,594	24,342
1.60%	0.868	92.3%	93.2%	5%	85%	1,820	31,140
1.60%	0.868	92.3%	93.2%	5%	80%	1,591	27,222

\* Sample sizes calculated using an initial HR of 0.868 and accounting for deaths from other causes as competing risks, with competing risk annual event rate of 1.8% and 1.85% in the usual care and aspirin arms respectively (see Section 9.1.1 for more details).

Even with the number of eligible patients per practice lower than expected at 300 and a consent rate of approximately 7.5%, full recruitment from HEAT's existing network of 1,200 practices should be possible for:

- >85% power to detect a risk reduction of 12.5% with an annual event rate of 1.8%, or
- >80% power to detect a risk reduction of 12.5% with an annual event rate of 1.6%.

#### 9.4 DROPOUT RATE

Follow-up for the major outcomes in ATTACK is based upon routinely collected hospital, GP and national mortality and cancer data. We will obtain baseline consent for these data to be collected. This will allow an ideal full intention-to-treat (ITT) analysis on all participants who are randomised with the exception of those who both withdraw from the study and remove their consent for data linkage, and it is for these participants that we are applying the term dropout. Patients who do not participate in annual follow-up for EQ-5D-5L and self-reported health events and health service contacts will still be followed up for major outcomes. Hence we have only factored in a small dropout rate of 1% in our sample size calculations. It is possible that the numbers stopping aspirin (especially because of side effects) and then not agreeing to follow-up may be greater than those experiencing usual care, but we believe this effect is likely to be very small and hence unlikely to be a source of significant bias, and we will monitor this.

#### 9.5 DATA ANALYSIS

A detailed statistical analysis plan will be developed and all data and appropriate documentation will be stored according to the archiving guidelines of the Sponsor.

##### 9.5.1 ASSESSMENT OF EFFICACY AND SAFETY

Primary outcome measure:

Time from randomisation to first major vascular event. A major vascular event is defined as a primary composite outcome of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death (excluding confirmed intracranial haemorrhage and other fatal cardiovascular haemorrhage).

Secondary outcome measures:

Efficacy

1. Time from randomisation to death from any cause

2. Time from randomisation to composite outcome of major vascular event or revascularisation (coronary and non-coronary)
3. Time from randomisation to individual components of the primary composite endpoint
4. Health-related quality of life

#### Safety

1. Time from randomisation to composite outcome of intracranial haemorrhage (fatal and non-fatal), fatal extracranial haemorrhage and non-fatal major extracranial haemorrhage (adjudicated)
2. Time from randomisation to fatal and non-fatal (reported individually and as a composite; subcategorised as traumatic and non-traumatic) intracranial haemorrhage comprising: i) primary haemorrhagic stroke (to distinguish from haemorrhagic transformation of ischaemic stroke): a) intracerebral and b) subarachnoid haemorrhage (reported individually and a composite) (adjudicated); ii) other intracranial haemorrhage: a) subdural and b) extradural haemorrhage (reported as a composite) (adjudicated)
3. Time from randomisation to fatal and non-fatal (reported individually and as a composite) major extracranial haemorrhage: i) upper gastrointestinal; ii) lower gastrointestinal; iii) sight-threatening ocular; iv) multiple trauma; v) other (adjudicated)
4. Time from randomisation to clinically relevant non-major bleeding (if hospitalised) (adjudicated)
5. Time from randomisation to composite outcome of fatal and non-fatal major extracranial haemorrhage and clinically relevant non-major bleeding (if hospitalised)

#### Tertiary (exploratory) outcome measures:

1. Time to TIA
2. Rate of unplanned hospitalisation
3. Rate of hospitalisation with heart failure
4. Time to new diagnosis of cancer (colorectal/other)
5. Time to death due to cancer (where cancer is underlying cause of death)
6. Time from randomisation to CKD progression
7. Time to new diagnosis of dementia
8. Time to major non-traumatic lower limb amputations

The primary outcome measure will be analysed for the ITT population. Deaths from other causes (including fatal bleeding) will be treated as competing events. Patients who do not experience a major vascular event will be censored at the date of last follow-up.

As non-fatal major bleeding and anticoagulation are events which, in the intervention arm, may lead to aspirin cessation, sensitivity analyses of the primary outcome measure (for the ITT population) will also include:

- Censoring patients who experience non-fatal major bleeding (adjudicated), clinically relevant non-major bleeding (if hospitalised), or anticoagulation at the date of the event (whichever occurs first)
- Censoring only patients who experience non-fatal major bleeding (adjudicated) at the date of the event

For the secondary outcomes of time to fatal/non-fatal major haemorrhage (both intracranial and extracranial), the following competing risk models will be used to assess impact of assumptions over competing risk and censoring:

- Deaths from other causes (excluding fatal bleeding) will be treated as competing events. Patients who experience a major vascular event will be censored at the date of the event. Patients who do not experience either a major vascular event or fatal/non-fatal major event will be censored at the date of last follow-up
- Major vascular events and deaths from other causes (excluding fatal bleeding) will be treated as competing events. Patients who do not experience a fatal/non-fatal major event will be censored at the date of last follow-up
- Major vascular events and deaths from other causes (excluding fatal bleeding) will be treated as competing events. Patients who experience anticoagulation or clinically relevant non-major bleeding (if hospitalised) will be censored at the date of the event (whichever occurs first). Patients who do not experience either anticoagulation, clinically relevant non-major bleeding (if hospitalised), or a fatal/non-fatal major event will be censored at the date of last follow-up
- Deaths from other causes (excluding fatal bleeding) will be treated as competing events. Patients who experience anticoagulation, clinically relevant non-major bleeding (if hospitalised), or a major vascular event will be censored at the date of the event (whichever occurs first). Patients who do not experience either anticoagulation, clinically relevant non-major bleeding (if hospitalised), a major vascular event or a fatal/non-fatal major event will be censored at the date of last follow-up

All primary, secondary and tertiary time to event outcomes will be described using Kaplan-Meier curves (or Cumulative Hazard plots for time to event outcomes involving competing risks) for the ITT population. Analyses of time to event outcomes will be performed using a Cox proportional hazards model (or Fine and Gray's adaptation of the Cox proportional hazards model for the subdistribution of a competing risk (118) i.e. a Competing Risk regression model for time to event outcomes involving competing risks), both unadjusted and adjusted for stratification factors: age, diabetes and CKD severity.

The adjusted competing risk regression model for time to first major vascular event, with deaths from other causes (including fatal bleeding) treated as competing events, and patients who do not experience a major vascular event censored at the date of last follow-up, will form the primary endpoint analysis model.

Other secondary and tertiary endpoints will be assessed by arm using summary statistics (e.g. Pearson's  $\chi^2$  tests) in the ITT population.

### **9.5.2 PROCEDURES FOR MISSING, UNUSED AND SPURIOUS DATA**

The amount of missing data and reasons for the incompleteness will be explored and presented overall i.e. not by group. If the amount of missing data is deemed too high and if appropriate (i.e. assuming the missing data is either missing at random (MAR) or missing completely at random (MCAR) and censoring assumed to be non-informative), multiple imputation will be performed accordingly, for which all covariates included in the multivariable model, together with the censoring/event indicator and the cumulative baseline hazard will be included in the multiple imputation model.

### **9.5.3 DEFINITION OF POPULATIONS ANALYSED**

All analyses will be carried out on the intention-to-treat (ITT) population. The ITT population is formed of all patients recruited and randomised to the trial.

#### 9.5.4 ECONOMIC ANALYSIS

Economic analysis will follow the methods and 'reference case' recommended by NICE (119). Modelling will be used to estimate the net effect of aspirin prescribing on healthcare costs and quality-adjusted survival over a lifetime horizon, using trial data to estimate effects on vascular and bleeding risks, cancer incidence, CKD progression and mortality. Trial data will also be used to estimate health-related quality of life and healthcare costs for the population and associated with adverse events.

Costs will be estimated using individual level linked HES/GP data, supplemented where necessary with information from the patient questionnaire. Costs will be estimated for services potentially affected by aspirin use, including:

- prescriptions (aspirin, gastroprotective and other related drugs)
- primary care consultations
- unplanned admissions for bleeds and vascular events, with related follow-up (e.g. revascularisations)
- renal replacement therapy following CKD progression

Unit costs for services will be obtained from standard national sources: NHS Reference Costs for admissions and other hospital services; Personal Social Services Research Unit (PSSRU) estimates for primary care and community services; and British National Formulary (BNF)/Drug Tariff for drug prices.

Quality-adjusted life years (QALYs) will be estimated using data on survival and quality of life (EQ-5D-5L) questionnaires. EQ-5D-5L data will be collected from all patients at baseline and at annual intervals. EQ-5D-5L scores ('utilities') will be calculated using a UK general population value set, as recommended by NICE at the time of analysis (120,121) Costs and QALYs will be discounted at NICE recommended rates (currently 3.5% per year for both).

The model structure, parameter sources and methods of analysis will be specified in a protocol paper, informed by a review of high quality CKD and CVD prevention models (identified from selected sources including relevant NICE technology appraisals and NIHR Journals Library publications) and agreed within the project team. We expect to use an individual-level discrete-event simulation approach to reflect the multiple, competing risks of vascular, haemorrhagic and other related events in this population over a lifetime horizon, taking advantage of the large pragmatic trial dataset (122). Distributions of baseline characteristics and risk factors will be estimated from trial data. Control arm data will be used to characterise event rates under usual care: e.g. using Cox proportional hazards predictive equations for CVD events and CKD progression; and parametric survival models (e.g. Gompertz) for all-cause survival (pre- and post- event, and by CKD stage or severity) (123). Relative treatment effects will be taken from the main trial analyses described in section 9.5.1 above (Cox proportional hazards or competing hazards regressions). The impact of events on patients' quality of life (EQ-5D-5L utility scores) and NHS costs will be estimated from trial data by an appropriate regression approach (124). If an effect on cancer incidence is found, this will be included in the economic model, although we may need to source background risk, cost and utility parameters for this outcome from the literature.

Uncertainty over model results will be explored through sensitivity analysis. Deterministic analysis will be used to investigate the sensitivity of results to input parameters and key modelling

assumptions. Probabilistic analysis will be used to assess the extent and impact of uncertainty over model inputs. Results will be stratified by pre-defined subgroups and CVD risk.

Validity of the model will be assessed by a Health Economist not involved in its development. This will include tests of internal validity: checks that input parameters match specified sources and inspection of coding (white box validation); stress testing of model behaviour (black box validation); and comparison of modelled event rates during the trial follow-up period with trial observations. External validity will be assessed by comparison of intermediate model results (event rates) with relevant estimates from the literature (identified by systematic review).

## 10. ADVERSE EVENTS

### 10.1 DEFINITIONS

Standard definitions related to adverse event reporting are summarised in Tables 7, 8 and 9.

Table 7. Defining adverse events

<p><b>Adverse Event (AE)</b></p>	<p>Any unfavourable and unintended sign, symptom, syndrome or illness that develops or worsens during the period of observation in the study.</p> <p>An AE <u>does</u> include a/an:</p> <ol style="list-style-type: none"> <li>1. Exacerbation of a pre-existing illness</li> <li>2. Increase in frequency or intensity of a pre-existing episodic event or condition</li> <li>3. Condition detected or diagnosed after medicinal product administration even though it may have been present prior to the start of the study</li> <li>4. Continuous persistent disease or symptoms present at baseline that worsen following the start of the study</li> </ol> <p>An AE <u>does not</u> include a/an:</p> <ol style="list-style-type: none"> <li>1. Medical or surgical procedure (e.g. surgery, endoscopy, tooth extraction, transfusion); but the condition that lead to the procedure is an AE</li> <li>2. Pre-existing disease or conditions present or detected at the start of the study that did not worsen</li> <li>3. Situations where an untoward medical occurrence has not occurred (e.g. hospitalisations for cosmetic elective surgery, social and/or convenience admissions)</li> <li>4. Disease or disorder being studied or sign or symptom associated with the disease or disorder unless more severe than expected for the participant's condition</li> <li>5. Overdose of concurrent medication without any signs or symptoms</li> </ol>
<p><b>Adverse Reaction (AR)</b></p>	<p>Any unfavourable and unintended sign, symptom, syndrome or illness that develops or worsens during the period of observation in the study which is related to IMP administered.</p>
<p><b>Serious Adverse Event (SAE)</b></p>	<p>Any adverse event occurring following study mandated procedures, having received the IMP, which results in any of the following outcomes:</p> <ol style="list-style-type: none"> <li>1. Death</li> <li>2. A life-threatening adverse event</li> <li>3. Inpatient hospitalisation or prolongation of existing hospitalisation (excluding: hospitalisation for routine treatment or monitoring; and treatment, which was elective or pre-planned, for a pre-existing condition that is unrelated to the indication under study, and has not worsened)</li> <li>4. A disability/incapacity</li> </ol>

	<p>5. A congenital anomaly in the offspring of a participant</p> <p>Important medical events that may not result in death, be life-threatening, or require hospitalisation may be considered a serious adverse event when, based upon appropriate medical judgment, they may jeopardise the patient or participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.</p> <p>A distinction is drawn between serious and severe AEs. Severity is a measure of intensity whereas seriousness is defined using the criteria above. Hence, a severe AE need not necessarily be serious.</p>
<b>Suspected Unexpected Serious Adverse Reaction (SUSAR)</b>	A serious adverse event that is “unexpected”, meaning that its nature and severity are not consistent with the information about the medicinal product in question set out in the summary of product characteristics is classed as a SUSAR and requires expedited reporting as per clinical trials regulations.

**Table 8. Defining causality**

<b>Not related or improbable</b>	A clinical event, including laboratory test abnormality, with temporal relationship to trial treatment administration which makes a causal relationship incompatible or for which other drugs, chemicals or disease provide a plausible explanation. This will be counted as “unrelated” for notification purposes.
<b>Possible</b>	A clinical event, including laboratory test abnormality, with temporal relationship to trial treatment administration which makes a causal relationship a reasonable possibility, but which could also be explained by other drugs, chemicals or concurrent disease. This definition will be used when drug causality is one of other possible causes for the described clinical event. It will be counted as “related” for notification purposes.
<b>Probable</b>	A clinical event, including laboratory test abnormality, with temporal relationship to trial treatment administration which makes a causal relationship a reasonable possibility, and is unlikely to be due to other drugs, chemicals or concurrent disease. This will be counted as “related” for notification purposes.
<b>Definite</b>	A clinical event, including laboratory test abnormality, with temporal relationship to trial treatment administration which makes a causal relationship a reasonable possibility, and which can definitely not be attributed to other causes. This will be counted as “related” for notification purposes.

An AE whose causal relationship to the study IMP is assessed by the Chief Investigator as “possible”, “probable”, or “definite” is an Adverse Drug Reaction (ADR). With regard to the criteria above, medical and scientific judgment shall be used in deciding whether prompt reporting is appropriate in that situation.

**Table 9. Defining expectedness**

<b>Expected</b>	A clinical event which is consistent with the information about the IMP listed in the Summary of Product Characteristics (SPC).
-----------------	---

<b>Unexpected</b>	A clinical event which is not consistent with the information about the IMP listed in the SPC.
-------------------	--

## 10.2 REPORTING OF ADVERSE EVENTS

Participating GPs/Study Site Coordinators will be asked to contact the Regional Centres and provide details of potential SAE that are not excluded in this Protocol (see below) as soon as they become aware of the event. Participants will also be asked to contact the study site in the event of any emergency hospital admission. They will carry a Trial Participant ID card which asks admitting hospitals to inform the Regional Centre of hospitalisations. Standard information will be collected and recorded on the CRF by the Regional Centre, including the nature and date of event, and reasons for attribution to study treatment. Further information will be sought as necessary.

Any participant who experiences an adverse event may be withdrawn from study treatment at the discretion of the Investigator(s), but will remain in the trial for follow-up unless they withdraw consent for this.

### 10.2.1 SERIOUS ADVERSE EVENTS

Aspirin was developed more than 100 years ago and has a very well-established side effect profile. There is extensive experience of the use of aspirin in people with kidney disease and it is recommended for the secondary prevention of CVD in people with CKD by NICE (80).

In this context the following events are exempted by the Protocol from expedited reporting using an SAE report form (in accordance with Section 32 Paragraph 4 of the Medicines for Human Use (Clinical Trials) Regulations 2004):

- events meeting the definition of SAE but which are listed as Undesirable Effects in the current Summary of Product Characteristics for aspirin (with the exception of hypersensitivity/allergic reactions which will subject to expedited reporting)
- anything that constitutes a trial endpoint, as this will be assessed as part of the trial
- SAE which in the opinion of the Investigator are with reasonable probability unrelated to aspirin

The Regional Centre will screen all potential SAEs (reported by Study Site Coordinators, trial subjects or admitting hospitals). Those not excluded within the Protocol will be recorded on an SAE report form. The Regional Principal Investigator (delegated responsibility from the Sponsor) will review causality, relatedness and expectedness, and forward the SAE report form to the Trial Coordinating Centre (as soon as possible and within 24 hours of becoming aware of the event) who will notify the Chief Investigator. SAEs identified in this way will be recorded and closely monitored until resolution, stabilisation, or until it has been shown that the study medication or treatment is not the cause. Confirmed reports will be promptly forwarded “unblinded” to the Chair of the DMEC.

Safety information relating to adverse events not subject to expedited reporting that are captured as trial endpoints will be closely monitored by the DMEC throughout the trial. The DMEC will be provided with a report (at a frequency [at least annual] specified by the DMEC) which will include the key safety-related trial outcomes.



## **10.2.2 SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTION**

All serious adverse events that fall or are suspected to fall within the criteria for a SUSAR shall be treated as such until deemed otherwise. The event shall be reported immediately (within 24 hours) of knowledge of its occurrence to the Chief Investigator.

The Chief Investigator will:

1. Assess the event for seriousness, expectedness and relatedness to the study IMP
2. Take appropriate medical action, which may include halting the trial and inform the Sponsor of such action
3. If the event is deemed a SUSAR, within seven days, enter the required data on the Medicines and Healthcare products Regulatory Agency (MHRA) eSUSAR web site
4. Inform the REC using the reporting form found on the NRES web page within 7 days of knowledge of the event
5. Within a further eight days send any follow-up information and reports to the MHRA and REC
6. Make any amendments as required to the study protocol and inform the ethics and regulatory authorities as required

## **10.2.3 DEVELOPMENT SAFETY UPDATE REPORTS**

The Trial Coordinating Centre will provide the Sponsor, REC and MHRA with Development Safety Update Reports. The reports will be submitted within 60 days of the anniversary date of the MHRA clinical trial authorisation (Developmental International Birth Date) of the trial each year until the trial is declared ended.

## **10.3 PREGNANCY**

Participants will be asked to inform their Regional Centre of any pregnancies (i.e. of female participants or female partners of male participants) which occur during the trial participation period. All pregnancies will be recorded on the CRF and followed up for outcome. Where it is the partner of a trial participant, consent will be obtained for this observation from both the partner and her medical practitioner. Any outcome meeting the definition of an AE/SAE will be reported to the Trial Coordinating Centre. The responsible clinician will adjust all medication as required for the pregnancy to continue as needed.

# **11. ETHICAL AND REGULATORY ASPECTS**

## **11.1 ETHICS COMMITTEE AND REGULATORY APPROVALS**

The trial will not be initiated before the Protocol, ICF and PIS have received approval/favourable opinion from the Sponsor, MHRA, REC, and the respective National Health Service (NHS) Research & Development (R&D) department. Should a protocol amendment be made that requires REC approval, the changes in the Protocol will not be instituted until the amendment and revised ICF and PIS (if appropriate) have been reviewed and received approval/favourable opinion from the REC and R&D departments. A protocol amendment intended to eliminate an apparent immediate hazard to participants may be implemented immediately providing that the MHRA, R&D and REC are notified as soon as possible and an approval is requested. Minor protocol amendments only for logistical or administrative changes may be implemented immediately; and the REC will be informed.

The trial will be conducted in accordance with: the ethical principles that have their origin in the Declaration of Helsinki, 1996; the principles of GCP, in accordance with the Medicines for Human Use Regulations, Statutory Instrument 2004, 1031 and its subsequent amendments; and the Department of Health Research Governance Framework for Health and Social care, 2005.

## **11.2 RECORDS**

### **11.2.1 CASE REPORT FORMS (CRF)**

Each participant will be assigned a screening number, and a trial randomisation number, allocated at randomisation, for use on trial documents and the electronic database. The documents and database will also use their initials and date of birth (dd/mm/yy).

CRFs will be treated as confidential documents and held securely in accordance with regulations. A separate confidential record of the participant's name, date of birth, local hospital number or NHS number, and Participant Trial Number (the Trial Recruitment Log) will be held securely on the trial database, to permit identification of all participants enrolled in the trial in accordance with regulatory requirements and for follow-up as required.

CRFs shall be restricted to those personnel approved by the Chief or local Principal Investigator and recorded on the 'Trial Delegation Log.' All paper forms shall be filled in using a dark pen. Errors shall be scored through and the correction inserted, initialled and dated. The Investigator shall sign a declaration attesting to the accuracy of data recorded in the CRF.

### **11.2.2 SOURCE DOCUMENTS**

Source documents will include the patient's electronic GP record, and their hospital records. In addition to this, a source data worksheet will be completed at the patient's consent visit by the research nurse, which will record basic demographic and clinical information about the patient, along with confirmation of inclusion/exclusion criteria. This will be filed in the Trial Master File held at each of the Regional Centres, along with a copy being stored in the site file at each trial practice (which can be scanned and uploaded to the patient's electronic GP record if desired). Only trial staff as listed on the Delegation Log shall have access to trial documentation other than the regulatory requirements listed below.

The CRF and all source documents shall made be available at all times for review by the Chief Investigator, Sponsor's designee and inspection by relevant regulatory authorities (MHRA).

## **11.3 DATA PROTECTION**

All trial staff and investigators will endeavour to protect the rights of the trial's participants to privacy and informed consent, and will adhere to the General Data Protection Regulation (GDPR). The CRF will only collect the minimum required information for the purposes of the trial. CRFs will be held securely, in a locked room, or locked cupboard or cabinet. Access to the information will be limited to the trial staff and investigators and relevant regulatory authorities (see above).

Computer held data including the trial database will be held securely and password protected. All data will be stored on a secure dedicated web server. Access will be restricted by user identifiers and passwords (encrypted using a one-way encryption method). Information about the trial in the

participant's medical records/hospital notes will be treated confidentially in the same way as all other confidential medical information.

Electronic data will be backed up every 24 hours to both local and remote media in encrypted format.

## **12. QUALITY ASSURANCE & AUDIT**

### **12.1 INSURANCE AND INDEMNITY**

Insurance and indemnity for trial participants and staff is provided through NHS schemes (under cover of HSG [96] 48) and Public Liability/Clinical Trials insurance. The Sponsor holds Public Liability (negligent harm) and Clinical Trials (negligent harm) insurance policies which apply to this trial. Indemnity for GP Study Site Co-ordinators is available through personal professional indemnity arrangements.

### **12.2 TRIAL CONDUCT**

Trial conduct will be subject to systems audit where appropriate of: the Trial Master File for inclusion of essential documents; permissions to conduct the trial; Trial Delegation Log; CVs of trial staff and training received; local document control procedures; consent procedures and recruitment logs; adherence to procedures defined in the protocol; adverse event recording and reporting; and equipment calibration logs.

### **12.3 TRIAL DATA**

Monitoring of trial data shall include: confirmation of informed consent; source data verification; data storage and data transfer procedures; local quality control checks and procedures; back-up and disaster recovery of any local databases; and validation of data manipulation. The Regional Centre team, or where required, a nominated designee of the Sponsor, shall carry out monitoring of trial data as an ongoing activity.

Entries on the trial database will be verified by inspection against the source data (a percentage as defined in the Monitoring Plan). Where corrections are required these will carry a full audit trail and justification.

Trial data and evidence of monitoring and systems audits will be made available for inspection by the regulatory authority as required.

The Sponsor will undertake proportionate annual review of the Regional Centres using a trial monitoring checklist.

It is recommended Individual Participant Data (IPD) from completed clinical trials should be responsibly shared to support efficient clinical research, generate new knowledge and bring benefit to patients (125). Participants will be informed that we intend to share IPD.

### **12.4 RECORD RETENTION AND ARCHIVING**

In compliance with the International Conference on Harmonisation (ICH) GCP guidelines, the Chief or Regional Principal Investigator will maintain all records and documents regarding the conduct of the study. These will be retained for up to 10 years after the date of any publication based on the research data. If the responsible investigator is no longer able to maintain the study records, a second person will be nominated to take over this responsibility.

The Trial Master File and trial documents held by the Chief Investigator on behalf of the Sponsor shall be finally archived at secure archive facilities at the University of Southampton. This archive shall include all trial databases and management software and associated meta-data encryption codes.

## **12.5 DISCONTINUATION OF THE TRIAL BY THE SPONSOR**

The Sponsor reserves the right to discontinue this trial at any time for failure to meet expected enrolment goals, for safety or any other administrative reasons. The Sponsor shall take advice from the Trial Steering Committee and Data Monitoring Committee as appropriate in making this decision.

## **12.6 STATEMENT OF CONFIDENTIALITY**

Individual participant medical information obtained as a result of this study are considered confidential and disclosure to third parties is prohibited with the exceptions noted above. Participant confidentiality will be further ensured by utilising identification code numbers to correspond to treatment data in the computer files.

Medical information may be given to the participant's medical team and all appropriate medical personnel responsible for the participant's welfare.

Data generated as a result of this trial will be available for inspection on request by the participating physicians, the University of Southampton representatives, the REC, local R&D Departments and the regulatory authorities.

## **13. PUBLICATION AND DISSEMINATION POLICY**

The study results will be presented at scientific meetings and will be the subject of peer-reviewed publications. Trial participants will not be identified in any publications. Patients will be informed of the results of the trial once they have been published.

## **14. USER AND PUBLIC INVOLVEMENT**

There will be a lay advisor on the Trial Management Group. Their role will be to advise on strategies for recruitment and follow up of participants, comment on study documents and advise on dissemination. There will also be two independent lay advisors on the Trial Steering Committee to give strategic input from a patient perspective.

The lay member on the TMG will have influence over the design of the trial and study documents and will be consulted at all stages of the research project.

## **15. STUDY FINANCES**

### **15.1 FUNDING SOURCE**

This study is funded by grants from the National Institute of Health Research Health Technology Assessment programme and the British Heart Foundation.


### **15.2 PARTICIPANT STIPENDS AND PAYMENTS**

Participants will not be paid to participate in the trial. Travel expenses will be offered.

## 16. SIGNATURE PAGES


Signatories to Protocol:

**Chief Investigator:** Prof Hugh Gallagher

Signature:  \_\_\_\_\_


Date: 24/09/2021

**Chief Investigator:** Prof Paul Roderick

Signature:  \_\_\_\_\_

Date: 24/09/2021

**Chief Investigator:** Dr Simon Fraser

Signature:  \_\_\_\_\_


Date: 24/09/2021

**Trial Statistician:** Beth Stuart

Signature: \_\_\_\_\_

Date: 24/09/2021

**Sponsor:** Alison Knight

Signature:  \_\_\_\_\_

Date: 24/09/2021

## REFERENCES

1. Aresu M, Chaudhury M, Diment E, Fuller E, Gordon-Dseagu V, Gunning N, et al. Health Survey for England 2009 Volume 1: Health and lifestyles. 2010;1:55–8.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. *JAMA* [Internet]. 2007 Nov 7;298(17):2038–47. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17986697>
3. KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl* [Internet]. 2013;3(1):4–4. Available from: [http://www.kdigo.org/clinical\\_practice\\_guidelines/pdf/CKD/KDIGO\\_CKD-MBD\\_GL\\_KI\\_Suppl\\_113.pdf%5Cnhttp://www.nature.com/doi/10.1038/kisup.2012.73%5Cnhttp://www.nature.com/doi/10.1038/kisup.2012.76](http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_CKD-MBD_GL_KI_Suppl_113.pdf%5Cnhttp://www.nature.com/doi/10.1038/kisup.2012.73%5Cnhttp://www.nature.com/doi/10.1038/kisup.2012.76)
4. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* [Internet]. 2011 Jul;80(1):17–28. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21150873>
5. Roderick P. Personal communication with Professor Gallagher. 2016.
6. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* (London, England) [Internet]. 2010 Jun 12;375(9731):2073–81. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20483451>
7. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int* [Internet]. 2011 Jun;79(12):1341–52. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21307840>
8. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. *Kidney Int* [Internet]. 2011 Jun;79(12):1331–40. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21289598>
9. Fox CS, Matsushita K, Woodward M, Bilo HJG, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet* (London, England) [Internet]. 2012 Nov 10;380(9854):1662–73. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23013602>
10. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. *Lancet* (London, England) [Internet]. 2012 Nov 10;380(9854):1649–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23013600>
11. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. *JAMA* [Internet]. 2012 Dec 12;308(22):2349–60. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23111824>
12. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. *Bmj* [Internet]. 2013;346(jan29 1):f324–f324. Available from: <http://www.bmj.com/cgi/doi/10.1136/bmj.f324>
13. Wen CP, Matsushita K, Coresh J, Iseki K, Islam M, Katz R, et al. Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. *Kidney Int* [Internet]. 2014 Oct;86(4):819–27. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24522492>

14. Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, et al. The clinical course of left ventricular hypertrophy in dialysis patients. *Nephron* [Internet]. 1990;55(2):114–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2141918>
15. de Zeeuw D, Parving H-H, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. *J Am Soc Nephrol* [Internet]. 2006 Aug;17(8):2100–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16825327>
16. Antithrombotic Trialists' Collaboration, Trialists A. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* [Internet]. 2002;324(7329):71–86. Available from: <http://view.ncbi.nlm.nih.gov/pubmed/11786451>
17. Trialists A, Collaboration ATT. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* [Internet]. 2009;373(9678):1849–60. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0140673609605031>
18. Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. *Arch Intern Med* [Internet]. 2012 Feb 13;172(3):209–16. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22231610>
19. Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala N-B, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. *Health Technol Assess* [Internet]. 2013 Sep;17(43):1–253. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24074752>
20. Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, et al. Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. *JAMA Oncol* [Internet]. 2016 Jun 1;2(6):762–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26940135>
21. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* (London, England). 2011 Jan;377(9759):31–41.
22. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *Lancet* (London, England). 2012 Apr;379(9826):1602–12.
23. Guirguis-Blake JM, Evans C V., Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: A systematic evidence review for the U.S. preventive services task force. *Ann Intern Med*. 2016;164(12):804–13.
24. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med* [Internet]. 2016 Jun 21;164(12):836–45. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27064677>
25. Mora S, Manson JE. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. *JAMA Intern Med* [Internet]. 2016 Aug 1;176(8):1195–204. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27322595>
26. Halvorsen S, Andreotti F, Ten Berg JM, Cattaneo M, Coccheri S, Marchioli R, et al. Aspirin therapy in primary cardiovascular disease prevention: A position paper of the European society of cardiology working group on thrombosis. *J Am Coll Cardiol*. 2014;64(3):319–27.
27. Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. *Lancet* [Internet]. 2017;390(10093):490–9. Available from: [http://dx.doi.org/10.1016/S0140-6736\(17\)30770-5](http://dx.doi.org/10.1016/S0140-6736(17)30770-5)
28. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(2 SUPPL.).
29. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans C V. Bleeding risks with

- aspirin use for primary prevention in adults: A systematic review for the U.S. preventive services task force. *Ann Intern Med.* 2016;164(12):826–35.
30. Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. *J Am Coll Cardiol [Internet].* 2010;56(4):254–63. Available from: <http://dx.doi.org/10.1016/j.jacc.2010.05.008>
  31. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. *Circulation [Internet].* 1998;98(18):1860–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9799205>
  32. Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. *Bmj [Internet].* 2012;344(jan25 2):d8059–d8059. Available from: <http://www.bmj.com/cgi/doi/10.1136/bmj.d8059>
  33. Elwood PC, Morgan G, Galante J, Chia JWK, Dolwani S, Graziano JM, et al. Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. *PLoS One [Internet].* 2016;11(11):e0166166. Available from: <http://dx.plos.org/10.1371/journal.pone.0166166>
  34. Rodriguez L, Hernandez-Diaz S, de Abajo F. Association between aspirin and upper gastrointestinal complications : Systematic review of epidemiologic studies. *Br J Clin Pharmacol.* 2001;52(November 2000):563–71.
  35. Rothwell P, Wilson M, Elwin C, Norrving B, Algra A, Warlow C, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality : 20-year follow-up of five randomised trials . *Lancet.* 2010;376(9754):1741–50.
  36. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *Lancet [Internet].* 2017 Dec 14;379(9826):1602–12. Available from: [http://dx.doi.org/10.1016/S0140-6736\(11\)61720-0](http://dx.doi.org/10.1016/S0140-6736(11)61720-0)
  37. De Berardis G, Lucisano G, D’Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. *JAMA [Internet].* 2012 Jun 6;307(21):2286–94. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22706834>
  38. Scheiman JM, Devereaux PJ, Herlitz J, Katelaris PH, Lanas A, Veldhuyzen van Zanten S, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). *Heart [Internet].* 2011 May;97(10):797–802. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21415072>
  39. Mo C, Sun G, Lu M-L, Zhang L, Wang Y-Z, Sun X, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. *World J Gastroenterol [Internet].* 2015 May 7;21(17):5382–92. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25954113>
  40. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID. *J Am Coll Cardiol [Internet].* 2010 Dec 7;56(24):2051–66. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21126648>
  41. Aung T, Haynes R, Barton J, Cox J, Murawska A, Murphy K, et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events in Diabetes (ASCEND). *Trials [Internet].* 2016;17(1):286. Available from: <http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1354-9>
  42. The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in



- Persons with Diabetes Mellitus. *New Engl J Med*. 2018;379:1529–39.
43. ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. *Contemp Clin Trials* [Internet]. 2013 Nov;36(2):555–64. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24113028>
  44. McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of Aspirin on Disability-free Survival in the Healthy Elderly. *N Engl J Med* [Internet]. 2018;(September):NEJMoa1800722. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1800722>
  45. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. *N Engl J Med* [Internet]. 2018;NEJMoa1805819. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1805819>
  46. A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE) [Internet]. Available from: <https://clinicaltrials.gov/ct2/show/NCT00501059>
  47. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2018;392(10152):1036–46.
  48. Bowman L, Mafham M, Stevens W, Haynes R, Aung T, Chen F, et al. ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. *Am Heart J* [Internet]. 2017;(2018). Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0002870317303927>
  49. McNeil JJ, Woods RL, Nelson MR, Murray AM, Reid CM, Kirpach B, et al. Baseline Characteristics of Participants in the ASPREE (ASpirin in Reducing Events in the Elderly) Study. *J Gerontol A Biol Sci Med Sci*. 2017;72(11):1586–93.
  50. Zheng S, Roddick A. Association of Aspirin Use for Primary Prevention of CVD With Cardiovascular Events and Bleeding. *JAMA - J Am Med Assoc* [Internet]. 2019;321(3):277–87. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2721178>
  51. Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis (Supplementary material). *JAMA - J Am Med Assoc*. 2019;321(3):277–87.
  52. Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. *Circulation* [Internet]. 2012 May 29;125(21):2649–61. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22644369>
  53. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Antiplatelet agents for chronic kidney disease. *Cochrane database Syst Rev* [Internet]. 2013 Feb 28;(2):CD008834. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23450589>
  54. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. *Am J Kidney Dis*. 2005;45(3):473–84.
  55. Rexrode KM. Analgesic Use and Renal Function in Men. *Jama* [Internet]. 2001;286(3):315. Available from: <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.286.3.315>
  56. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. *Arch Intern Med*. 2004;164:1519–24.
  57. Kim AJ, Lim HJ, Ro H, Ko K-P, Han SY, Chang JH, et al. Low-Dose Aspirin for Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. *PLoS One* [Internet]. 2014;9(8):e104179. Available from: <http://dx.plos.org/10.1371/journal.pone.0104179>
  58. Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. *J Am Coll Cardiol* [Internet]. 2010 Sep 14;56(12):956–65. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20828648>
  59. Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, et al. Is long-term low-dose aspirin therapy associated with renal dysfunction in patients with type 2 diabetes?

- JPAD2 cohort study. PLoS One. 2016;11(1):1–12.
60. Tanrikulu AM, Ozben B, Koc M, Papila-Topal N, Ozben T, Caymaz O. Aspirin resistance in patients with chronic renal failure. J Nephrol [Internet]. 24(5):636–46. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21279952>
  61. Polzin A, Dannenberg L, Sansone R, Levkau B, Kelm M, Hohlfeld T, et al. Antiplatelet effects of aspirin in chronic kidney disease patients. J Thromb Haemost. 2016;14(2):375–80.
  62. Gremmel T, Muller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant [Internet]. 2013;28(8):2116–22. Available from: <https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gft103>
  63. Breet NJ, de Jong C, Bos WJ, van Werkum JW, Bouman HJ, Kelder JC, et al. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thromb Haemost [Internet]. 2014 Sep 18 [cited 2017 Nov 8];112(6):1174–81. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25231776>
  64. Best PJM, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. Am Heart J. 2008;155(4):687–93.
  65. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med [Internet]. 2016;176(2):238. Available from: <http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2015.7193>
  66. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482–94.
  67. Tomlinson LA, Fogarty DG, Douglas I, Nitsch D. Pharmacoepidemiology for nephrologists: Do proton pump inhibitors cause chronic kidney disease? Nephrol Dial Transplant. 2017;32(November):ii40–6.
  68. Chan FKL, Kyaw M, Tanigawa T, Higuchi K, Fujimoto K, Cheong PK, et al. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin. 2017 [cited 2017 Nov 9]; Available from: <http://bit.ly/1q51BIW>.
  69. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–62.
  70. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes. JAMA - J Am Med Assoc [Internet]. 2008;300(18):2134–41. Available from: <http://hinarilogin.research4life.org/uniquesigjama.jamanetwork.com/uniquesig0/article.aspx?articleid=182877&resultClick=3>
  71. Major RW, Oozeerally I, Dawson S, Riddleston H, Gray LJ, Brunskill NJ. Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. Atherosclerosis [Internet]. 2016;251:177–82. Available from: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.06.013>
  72. Wolfe R, Wetmore JB, Woods RL, McNeil JJ, Gallagher H, Roderick P, et al. Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney Int. 2021;
  73. Major RW, Burton JO. “To take or not to take an aspirin?” The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease. Kidney Int. 2021;99(2):308–10.

74. Dad T, Weiner DE. Does an Aspirin a Day Keep the Doctor Away? *Am J Kidney Dis*. 2017;69(3):337–40.
75. Department of Health. Cardiovascular Disease Outcomes Strategy Improving outcomes for people with or at risk of cardiovascular disease. 2013;89.
76. Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. *Nephrol Dial Transplant* [Internet]. 2012 Oct;27 Suppl 3:iii73-80. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22815543>
77. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet* (London, England) [Internet]. 2011 Jun 25;377(9784):2181–92. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21663949>
78. Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW. Chronic Kidney Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study. *PLoS Med*. 2016;13(9):1–16.
79. Taal M. Personal communication with Professor Gallagher 2017. 2017.
80. National Institute for Health and Care Excellence (NICE). Chronic kidney disease in adults : assessment and management. 2014;(January):Available from <https://www.nice.org.uk/guidance/cg>.
81. Major R, Shepherd D, Warwick G, Brunskill N. Prescription Rates of Cardiovascular Medications in a Large UK Primary Care Chronic Kidney Disease Cohort. *Nephron* [Internet]. 2016;133(1):15–22. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27160883>
82. Margolis KL, Mahady SE, Nelson MR, Ives DG, Satterfield S, Britt C, et al. Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. *Contemp Clin Trials Commun*. 2018;11(May):30–6.
83. Avenell A, Grant AM, McGee M, McPherson G, Campbell MK, McGee MA. The effects of an open design on trial participant recruitment, compliance and retention--a randomized controlled trial comparison with a blinded, placebo-controlled design. *Clin Trials* [Internet]. 2004;1(6):490–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16279289>
84. Kohro T, Yamazaki T. Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design. *Hypertens Res*. 2009;32(August 2008):109–14.
85. Hatlen G, Romundstad S, Hallan SI. The accuracy of predicting cardiovascular death based on one compared to several albuminuria values. *Kidney Int*. 2014;85(6):1421–8.
86. UK Medicines Information (UKMi). What is the risk of gastrointestinal bleeding associated with selective serotonin reuptake inhibitors (SSRIs) [Internet]. 2013. Available from: <https://www.surreyandsussex.nhs.uk/wp-content/uploads/2013/04/UKMi-Risk-of-GI-Bleeding-with-SSRIs.pdf>
87. Prescribing and Primary Care H and SCIC. Quality and Outcomes Framework – Prevalence, Achievements and Exceptions Report 2015-2016. 2016. 1–43 p.
88. Public Health England. Chronic kidney disease prevalence model. 2014;1–6. Available from: [www.yhpho.org.uk/resource/view.aspx?RID=204692](http://www.yhpho.org.uk/resource/view.aspx?RID=204692)
89. Nitsch D, Caplin B, Hull S, Wheeler D. National Chronic Kidney Disease Audit. 2017;(January).
90. Mackenzie IS, Ford I, Walker A, Hawkey C, Begg A, Avery A, et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. *BMJ Open* [Internet]. 2016;6(9):e013774. Available from: <http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2016-013774>
91. Li L, Rothwell PM. Biases in detection of apparent “weekend effect” on outcome with administrative coding data: Population based study of stroke. *BMJ*. 2016;353.
92. ASCEND: A Study of Cardiovascular Events iN Diabetes. Protocol. Version 9. 2011.
93. Tyson JE, Pedroza C, Wallace D, D'Angio C, Bell EF, Das A. Stopping guidelines for an

- effectiveness trial: What should the protocol specify? *Trials*. 2016;17(1):1–4.
94. Nissen SE. ADAPT: The Wrong Way to Stop a Clinical Trial. *PLoS Clin Trials* [Internet]. 2006;1(7):e35. Available from: <http://dx.plos.org/10.1371/journal.pctr.0010035>
  95. Dumbleton JS, Avery AJ, Coupland C, Hobbs FDR, Kendrick D, Moore M V., et al. The Helicobacter Eradication Aspirin Trial (HEAT): A Large Simple Randomised Controlled Trial Using Novel Methodology in Primary Care. *EBioMedicine* [Internet]. 2015;2(9):1200–4. Available from: <http://dx.doi.org/10.1016/j.ebiom.2015.07.012>
  96. Knighton P. National Diabetes Audit Mortality Analysis. 2013; Available from: <http://www.hscic.gov.uk>
  97. Dumbleton J. Personal communication with Professor Gallagher. 2017.
  98. NIHR. Research Delivery in the NHS 2016-2017. *Natl Inst Heal Res Clin Res Netw* [Internet]. 2017;2017. Available from: <https://www.crn.nihr.ac.uk/about-crn/our-performance/key-statistics-2/>
  99. Awtry EH, Loscalzo J. Aspirin. *Circulation* [Internet]. 2000 Mar 14;101(10):1206–18. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10715270>
  100. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. *Stroke* [Internet]. 2006 Aug;37(8):2153–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16794200>
  101. Walker J, Robinson J, Stewart J, Jacob S. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? *Interact Cardiovasc Thorac Surg* [Internet]. 2007 Aug;6(4):519–22. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17669925>
  102. Chubak J, Kamineni A, Buist DSM, Anderson ML, Whitlock EP. Aspirin Use for the Prevention of Colorectal Cancer : An Updated Systematic Evidence Review for the U . S . Preventive Services Task Force. *Evid Synth*. 2015;(133):i–116.
  103. Wolfe R. Personal communication with Professor Gallagher - 2017. 2017.
  104. Tai B, Chen Z, Machin D. Estimating sample size in the presence of competing risks – Cause-specific hazard or cumulative incidence approach? *Stat Methods Med Res* [Internet]. 2015 Dec 27 [cited 2017 Nov 29];096228021562310. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26711503>
  105. Pintilie M. Dealing with competing risks: testing covariates and calculating sample size. *Stat Med* [Internet]. 2002 Nov 30 [cited 2018 Feb 8];21(22):3317–24. Available from: <http://doi.wiley.com/10.1002/sim.1271>
  106. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. *Lancet (London, England)* [Internet]. 2012 Sep 1;380(9844):807–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22717317>
  107. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. *JAMA* [Internet]. 1991 Jun 26;265(24):3255–64. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/2046107>
  108. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet (London, England)* [Internet]. 1997 Sep 13;350(9080):757–64. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/9297994>
  109. The ALLHAT Officers. Major Outcomes in High-Risk Hypertensive Patients Randomized to or Calcium Channel Blocker vs Diuretic. *J Am Med Assoc*. 2002;288(23):2981–97.
  110. Evans GW, Byington RP, C D, Grimm RH, Cutler JA, Simons-morton DG, et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *New Engl J Med*. 2010;1575–85.
  111. Rashidi A, Sehgal AR, Rahman M, O'Connor AS. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. *Am J Cardiol* [Internet]. 2008 Dec

- 15;102(12):1668–73. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19064021>
112. Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al. Impact of age on the association between CKD and the risk of future coronary events. *Am J Kidney Dis* [Internet]. 2014 Sep;64(3):375–82. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24751168>
  113. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015;373(22):2103–16.
  114. Nitsch D. Personal communication with Professor Gallagher. 2017.
  115. de Lusignana S, Gallagher H, Jones S, Chan T, van Vlymen J, Tahir A, et al. Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results. *Kidney Int* [Internet]. 2013;84(3):609–20. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0085253815560171>
  116. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). *Lancet* (London, England) [Internet]. 2005 Nov 19;366(9499):1773–83. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16298214>
  117. Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. *N Engl J Med* [Internet]. 2016 May 26;374(21):2009–20. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27041480>
  118. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. *J Am Stat Assoc* [Internet]. 1999 Jun [cited 2017 Nov 30];94(446):496–509. Available from: <http://www.tandfonline.com/doi/abs/10.1080/01621459.1999.10474144>
  119. NICE. Guide to the methods of technology appraisal. 2013;(April 2013).
  120. Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Heal* [Internet]. 2012;15(5):708–15. Available from: <http://dx.doi.org/10.1016/j.jval.2012.02.008>
  121. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. *Health Econ* [Internet]. 2017;(June):1–16. Available from: <http://doi.wiley.com/10.1002/hec.3564>
  122. Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Möller J. Modeling using discrete event simulation: A report of the ISPOR-SMDM modeling good research practices task force-4. *Value Heal* [Internet]. 2012;15(6):821–7. Available from: <http://dx.doi.org/10.1016/j.jval.2012.04.013>
  123. Mihaylova B, Schlackow I, Herrington W, Lozano-Kühne J, Kent S, Emberson J, et al. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). *Am J Kidney Dis* [Internet]. 2016 Apr;67(4):576–84. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26597925>
  124. Kent S, Schlackow I, Lozano-Kühne J, Reith C, Emberson J, Haynes R, et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? *BMC Nephrol* [Internet]. 2015;16(1):65. Available from: <http://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-015-0054-0>
  125. Tudur Smith C, Hopkins C, Sydes MR, Woolfall K, Clarke M, Murray G, et al. How should individual participant data (IPD) from publicly funded clinical trials be shared? *BMC Med*. 2015;13(1):1–7.
  126. Thygesen K, Jaffe AS, Chaitman BR, Canada PJD. Fourth Universal Definition of Myocardial Infarction ( 2018 ). *J Am Coll Cardiol* [Internet]. 2018; Available from: <https://doi.org/10.1016/j.jacc.2018.08.1038>
  127. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. *J Clin Epidemiol* [Internet]. 1988;41(2):105–14. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/3335877>
  128. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. *N Engl J Med* [Internet]. 2016;375(1):35–43. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1603060>

129. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N Engl J Med* [Internet]. 2017;NEJMoa1709118. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa1709118>
130. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL, et al. Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials. 2014;1–33.
131. Hicks KA, Mahaffey KW, Meran R, Nissen SE. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Circulation*. 2018;137:961–72.
132. ASPREE Protocol Version 9 November 2014.
133. Halkes PHA, Van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Classification of cause of death after stroke in clinical research. *Stroke*. 2006;37(6):1521–4.
134. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost*. 2005;3(4):692–4.
135. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. *J Thromb Haemost*. 2015;13(11):2119–26.
136. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. *JAMA* [Internet]. 2014 Jun 25;311(24):2518–31. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24892770>
137. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. *J Am Soc Nephrol* [Internet]. 2003 Jul;14(7 Suppl 2):S148-53. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12819321>
138. Glossary | NICE. [cited 2017 Dec 21]; Available from: <https://www.nice.org.uk/glossary>

## APPENDIX 1: DEFINITION OF CLINICAL ENDPOINTS

<p><b>Major vascular event</b></p>	<p>Composite outcome of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death (excluding confirmed intracranial haemorrhage and other fatal cardiovascular haemorrhage)</p>
<p><b>Non-fatal myocardial infarction</b></p>	<p>This is defined according to the Fourth Universal Definition of MI (126), included in full for reference. However events will be adjudicated pragmatically on the basis of the available information. Further detail (from the ATTACK Endpoint Adjudication Charter) is available on request. Note:</p> <ul style="list-style-type: none"> <li>• Primary adjudication outcome will be MI or not MI. It is recognised that distinguishing between Type 1 and Type 2 MI on the basis of the information available will be challenging. Where the discharge summary strongly implies a Type 2 MI (for example documented severe anaemia or atrial fibrillation with a minor troponin rise) the event will be recorded as Type 2; otherwise all will be labelled as Type 1. The primary outcome measure will include all MI within the composite, with a secondary analysis reporting on Type 1 MI only.</li> <li>• It is likely that in many cases it will be unclear whether biomarker criteria for acute MI described below are met. In these examples the disease codes and narrative from the discharge summary will be used to reach a judgement on whether an MI has taken place.</li> <li>• As in the ASCEND trial, prior/silent MI is excluded</li> </ul> <p><u>Criteria for myocardial injury</u></p> <p>The term myocardial injury is used when there is evidence of elevated cardiac troponin values (cTn) with at least 1 value above the 99th percentile upper reference limit (URL). The myocardial injury is considered acute if there is a rise and/or fall of cTn values.</p> <p><u>Criteria for acute myocardial infarction (Types 1, 2 and 3 MI)</u></p> <p>The term acute myocardial infarction is used when there is acute myocardial injury with clinical evidence of acute myocardial ischemia and with detection of a rise and/or fall of cTn values with at least 1 value above the 99th percentile URL and at least 1 of the following:</p> <ul style="list-style-type: none"> <li>• Symptoms of myocardial ischaemia;</li> <li>• New ischemic ECG changes;</li> <li>• Development of pathological Q waves;</li> <li>• Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology;</li> <li>• Identification of a coronary thrombus by angiography or autopsy (not for types 2 or 3 MIs)</li> </ul> <p>Post-mortem demonstration of acute atherothrombosis in the artery supplying the infarcted myocardium meets criteria for Type 1 MI.</p>

	<p>Evidence of an imbalance between myocardial oxygen supply and demand unrelated to acute atherothrombosis meets criteria for Type 2 MI.</p> <p>Cardiac death in patients with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes before cTn values become available or abnormal meets criteria for Type 3 MI.</p> <p><u>Criteria for coronary procedure–related myocardial infarction (Types 4 and 5 MI)</u></p> <p>These are as described within the Fourth Universal Definition of MI (126).</p> <p><u>ECG criteria consistent with myocardial ischaemia</u></p> <ul style="list-style-type: none"> <li>• ST elevation. New ST elevation at the J point in two contiguous leads with the cut-points: <math>\geq 0.1</math> mV in all leads other than leads V2-V3 where the following cut-points apply: <math>\geq 0.2</math> mV in men <math>\geq 40</math> years (<math>\geq 0.25</math> mV in men <math>&lt; 40</math> years) or <math>\geq 0.15</math> mV in women regardless of age</li> <li>• ST depression and T-wave changes. New horizontal or down-sloping ST depression <math>\geq 0.5</math> mm in two contiguous leads and/or new T inversion <math>&gt; 1</math> mm in two contiguous leads with prominent R wave or R/S ratio <math>&gt; 1</math></li> </ul> <p>Lesser ECG abnormalities may represent an ischaemic response. In patients with known or high likelihood of coronary artery disease, the clinical presentation is critical to enhance the specificity of these findings.</p> <p><u>Myocardial injury/infarction associated with CKD</u></p> <ul style="list-style-type: none"> <li>• Many patients with CKD have raised cTn</li> <li>• Diagnosing MI in patients with CKD and elevated cTn may be difficult if symptoms or ECG changes absent</li> <li>• However serial changes in cTn are equally effective in diagnosing MI in those with and without CKD</li> </ul> <p>If a rising or falling pattern is present the aetiology of the abnormal cTn values could be acute volume overload, congestive heart failure or MI. If a rising or falling pattern is accompanied by ischaemic symptoms, new ischaemic ECG changes or loss of viable myocardium on imaging, a diagnosis of acute MI is likely</p>
<p><b>Non-fatal stroke</b></p>	<p>Defined in accordance with the World Health Organization (WHO) definition as “rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer, with no apparent cause other than of vascular origin” (127) This excludes cases of primary cerebral tumour, cerebral metastasis, subdural haematoma, post-seizure palsy, brain trauma and TIA. Events will be adjudicated pragmatically (further detail in Endpoint Adjudication Charter, available on request).</p> <p>Haemorrhagic stroke (fatal and non-fatal) which has been confirmed on appropriate imaging (see below) is excluded from the primary composite endpoint and included within the secondary endpoints.</p>



	<p>Haemorrhagic transformation of a primary ischaemic stroke is included within the primary endpoint.</p> <p>Haemorrhagic stroke includes both intracerebral and subarachnoid haemorrhage (128,129).</p> <p>Uncertain stroke will be characterised as ischaemic.</p>
<p><b>Cardiovascular death</b></p>	<p>Defined largely according to the work of the Standardised Data Collection for Clinical Trials Initiative (130,131), with the difference that deaths due to intracranial haemorrhage (haemorrhagic stroke, non-stroke intracranial haemorrhage) and other elements of death due to cardiovascular haemorrhage (for example non-procedural or non-traumatic vascular rupture, or haemorrhage causing cardiac tamponade) are, as safety events rather than efficacy targets, excluded from the primary composite endpoint and included within the secondary endpoints.</p> <p>The aim of adjudication is to capture the primary cause of death, defined as the underlying disease that initiated the chain of events resulting in death (as opposed to the mode of death which is the physiological derangement or biochemical disturbance produced by the cause of death). Non-cardiovascular causes of death may culminate in a cardiovascular mode of death (from example renal failure cause dysrhythmia) – these will not be regarded as CV deaths (131).</p> <p>Cardiovascular death is subdivided as follow:</p> <ul style="list-style-type: none"> <li>• Death due to acute MI, defined as one of: <ul style="list-style-type: none"> <li>○ Death by any cardiovascular mechanism ≤30 days after a MI (definite or suspected (132))</li> <li>○ Death resulting from a procedure to treat a MI or a complication resulting from MI</li> <li>○ Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes or LBBB, but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be increased (126)</li> </ul> </li> <li>• Sudden cardiac death is a death that occurs unexpectedly, not following an acute MI, and includes the following deaths: <ul style="list-style-type: none"> <li>○ Death witnessed and occurring without new or worsening symptoms</li> <li>○ Death witnessed within 60 minutes of the onset of new or worsening cardiac symptoms, unless the symptoms suggest acute MI</li> <li>○ Death witnessed and attributed to an identified arrhythmia (e.g. captured on an ECG recording, witnessed on a monitor, or unwitnessed but found on implantable cardioverter-defibrillator review)</li> <li>○ Death after unsuccessful resuscitation from cardiac arrest (e.g. implantable cardioverter defibrillator unresponsive sudden cardiac death, pulseless electrical activity arrest)</li> <li>○ Death after successful resuscitation from cardiac arrest and without identification of a specific cardiac or non-cardiac aetiology</li> <li>○ Unwitnessed death in a subject seen alive and clinically stable ≤24 hours prior to being found dead without any evidence supporting a specific non-cardiovascular cause of death</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>• Death due to stroke where the death is either a direct consequence of the stroke or a complication of the stroke. Confirmed haemorrhagic stroke is included within the secondary endpoints (under fatal intracranial bleed)</li> <li>• Death due to heart failure, where the death is in association with clinically worsening symptoms and/or signs of heart failure regardless of heart failure aetiology</li> <li>• Death due to cardiovascular procedures, where the death is caused by the immediate complications of a cardiac procedure (excluding deaths from procedures to treat an MI)</li> <li>• Death due to other cardiovascular causes is a cardiovascular death not included in the above categories (and not due to intracranial or cardiovascular haemorrhage) but with a specific, known cause (e.g. pulmonary embolism or peripheral arterial disease)</li> </ul> <p>Death due to cardiovascular haemorrhage is a cardiovascular death related to haemorrhage such as non-procedural or non-traumatic vascular rupture, or haemorrhage causing cardiac tamponade. This is included within the secondary endpoints (under fatal extracranial bleed).</p> <p>It is expected that the definitions for fatal stroke and MI will be operationalised as follows:</p> <p><u>Coronary heart disease</u></p> <ul style="list-style-type: none"> <li>• Death on same calendar day as myocardial infarct will be classified as fatal MI (unless there is clear evidence for alternative cause of death)</li> <li>• Death up to 30 days after definite/probable MI which is due to any cardiovascular mechanism OR where the cause of death is unknown will be classified as fatal MI (single event)</li> <li>• Death up to 30 days after MI where a non-CV cause of death can be determined/deduced will be classified as non-fatal MI followed by non-CV death event (two events)</li> <li>• Death from any cause more than 30 days after MI will be classified as non-fatal MI followed by death event (two events)</li> </ul> <p><u>Stroke (133)</u></p> <ul style="list-style-type: none"> <li>• Death up to 30 days after stroke regardless of severity will be classified as fatal stroke (single event) unless there is evidence for an undeniable other cause of death (eg MI, malignancy, accidental) (which will be classified as non-fatal stroke followed by non-stroke death event)</li> <li>• Death more than 30 days after severe stroke (value judgement; equivalent to modified Rankin Score &gt;3) will be classified as fatal stroke (single event) unless there is evidence for an undeniable other cause of death, eg MI, malignancy, accidental (which will be classified as non-fatal stroke followed by non-stroke death event)</li> <li>• Death more than 30 days after non-severe stroke (equivalent to modified Rankin Score 3 or less) will be classified as death due to other cause (non-fatal stroke followed by non-stroke death)</li> </ul>
<p><b>Haemorrhagic stroke</b></p>	<p>Defined in accordance with the World Health Organization (WHO) definition of stroke as “rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no</p>

	<p>apparent cause other than of vascular origin” (127), and including both intracerebral haemorrhage and subarachnoid haemorrhage.</p> <p>Events will be adjudicated pragmatically. Where source data is available, the approach of the ASPREE investigators will be followed to confirm the diagnosis:</p> <ul style="list-style-type: none"> <li>• CT scanning demonstrates an area of hyperdensity within the brain parenchyma with or without extension into the ventricles or subarachnoid space or, for scans performed beyond 1 week, an area of attenuation with ring enhancement after injection of contrast, or</li> <li>• MRI scanning shows an area of hypointensity or isointensity on T1-weighted images or an area of marked hypointensity on gradient echo and T2-weighted images, or</li> <li>• autopsy demonstrates the origin of the hemorrhage as the cerebral parenchyma (132)</li> </ul>
<p><b>Intracranial haemorrhage</b></p>	<p>Includes intracerebral haemorrhage, subarachnoid haemorrhage, subdural haemorrhage, and epidural haemorrhage. For reporting purposes, subdural and epidural haemorrhage will be grouped and recorded as other intracranial haemorrhage. Intracranial haemorrhage will also be categorised as traumatic or non-traumatic (82).</p>
<p><b>Major extracranial haemorrhage</b></p>	<p>Major extracranial bleeding is defined as:</p> <ul style="list-style-type: none"> <li>• Fatal bleeding, or</li> <li>• Symptomatic bleeding in a critical area or organ, such as intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, or</li> <li>• Bleeding that leads to the transfusion of two or more units of whole blood or red cells</li> </ul> <p>Major bleeds are those that result in death, are life-threatening, cause chronic sequelae or consume major health-care resources. In particular, to be classified as major, bleeds in a critical area or organ should:</p> <ul style="list-style-type: none"> <li>• Be associated with a symptomatic clinical presentation (not following an incidental finding)</li> <li>• Be the cause of the symptoms</li> </ul> <p>The definitions follow the recommendations of the International Society for Thrombosis and Haemostasis (ISTH) (134), with the difference that “bleeding causing a fall in hemoglobin level of 20 g/L or more” is included within the ISTH definition but excluded in ATTACK. Change in haemoglobin has been removed because patients with CKD may have, or develop, anaemia as a direct result of the kidney disease, and may be treated with erythropoietin which will result in fluctuations in the haemoglobin concentration, making the relationship between bleeding and haemoglobin level less clear. A change in haemoglobin was also excluded from their definition of “clinically significant bleeding” by the ASPREE investigators (82).</p>

	<p>In ASPREE “clinically significant bleeding” was defined as bleeds at any site that required hospitalisation, prolonged hospitalisation, transfusion, surgery or were fatal (132). In the case of ASCEND “major haemorrhage” was any bleeding episode (excluding cerebral haemorrhage) that required hospitalisation or transfusion, or was fatal or disabling (92).</p> <p>Unlike in ASPREE or ASCEND, hospitalisation or prolongation of hospitalisation <i>per se</i> are not criteria for major bleeding in ATTACK. This follows the approach of the ISTH, justified “because bleeding is extremely unlikely to be the primary cause of serious medical consequences without also satisfying one of the included criteria for major bleeding, and inclusion of this criterion has the potential to falsely classify a minor bleed as a major bleed because of the coincidental occurrence of other conditions (134)”.</p> <p>It is recognised that in many cases the information available from the primary data source will be insufficient to determine beyond doubt whether the criteria for major bleeding have been met. In such cases surrogate markers of major bleeding reported in the discharge summary will also be acceptable:</p> <ul style="list-style-type: none"> <li>• Bleeding with reported or implied haemodynamic compromise</li> <li>• Bleeding requiring urgent surgery or angiography for haemostasis</li> <li>• GI bleeding for which urgent inpatient endoscopy is arranged</li> </ul> <p>The following decision rules, adapted from ASPREE (82), will also be followed:</p> <ul style="list-style-type: none"> <li>• Bleeding following elective inpatient surgery or endoscopic procedures is not counted as major bleeding (even if other markers of severity such as transfusion are evident)</li> <li>• Readmission for bleeding after elective surgical or endoscopic procedure, or admission after elective outpatient surgical or endoscopic procedure will be counted as major bleeding if any other markers of severity present</li> <li>• Bleeding following non-elective inpatient surgical or endoscopic procedure will be counted as major bleeding if any other markers of severity present</li> </ul> <p>The source of major extracranial bleeding will be categorised as upper gastrointestinal, lower gastrointestinal, sight-threatening ocular, multiple trauma and other (42,82).</p>
<p><b>Clinically relevant non-major bleeding</b></p>	<p>Defined in accordance with the ISTH as any sign or symptom of haemorrhage (e.g. more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria:</p> <ul style="list-style-type: none"> <li>• Requiring medical intervention by a healthcare professional</li> <li>• Leading to hospitalisation or increased level of care</li> <li>• Prompting a face to face (i.e. not just a telephone or electronic communication) evaluation (135)</li> </ul> <p>This definition includes all minor bleeding episodes that lead to medical evaluation involving direct patient contact.</p>

	<p>Ascertainment of CRNBM in an open trial will be subject to bias. We will therefore confine our reporting of CRNMB to that leading to hospitalisation or occurring as a hospital inpatient, as this will be formally adjudicated.</p> <p>CRNMB outside hospital will be logged from coded GP events but not formally reported.</p>
<b>Death from any cause</b>	<p>Cause of death will be ascertained from death certificates or post-mortem reports and classified as:</p> <ul style="list-style-type: none"> <li>• Cardiovascular death (within the primary endpoint, excluding intracranial haemorrhage and other cardiovascular haemorrhage)</li> <li>• Death due to haemorrhagic stroke</li> <li>• Death due to other intracranial haemorrhage</li> <li>• Death due to extracranial haemorrhage</li> <li>• Death due to cancer</li> <li>• Other non-cardiovascular death (a definitive non-cardiovascular/non-haemorrhagic cause of death must be identified)</li> <li>• Undetermined cause of death.</li> </ul> <p>A common analytic approach for cause of death analyses is to assume that all undetermined cases are included in the CV category (e.g., presumed CV death, specifically “death due to other CV causes”) (131), and this approach will be followed in ATTACK.</p>
<b>Revascularisation</b>	<p>Will include open and percutaneous coronary and non-coronary (including carotid, aortic and limb) procedures (as defined in OPCS-4 procedure codes) and will be ascertained from HES data (not adjudicated).</p>
<b>Major lower limb amputation</b>	<p>A major lower limb amputation is defined as the surgical removal of a part or whole limb proximal to the ankle, not performed as a result of traumatic injury. Will be ascertained from HES data (not adjudicated).</p>
<b>Hospitalisation</b>	<p>Defined as an official admission that is for a duration greater than 24 hours or a minimum of two calendar days where exact time of stay is unavailable. HES will serve as primary data source (not adjudicated).</p>
<b>Hospitalisation with heart failure</b>	<p>HES will serve as primary data source (not adjudicated).</p>
<b>Transient ischaemic attack</b>	<p>TIA will be ascertained from HES data and also from GP coded data as many TIA will be treated outside hospital (not adjudicated).</p>
<b>New diagnosis of dementia</b>	<p>GP codes will serve as primary data source (not adjudicated).</p>

<b>Cancer registrations</b>	ONS/HES will serve as primary data source (not adjudicated).
<b>CKD progression</b>	<p>Defined as at least one of:</p> <ul style="list-style-type: none"> <li>• &gt;30% fall in eGFR over two years (136), or</li> <li>• need for renal replacement therapy or 50% decline in eGFR (137), or</li> <li>• new eGFR&lt;15mL/min/1.73m<sup>2</sup>, or</li> <li>• 25% decline in GFR together with a drop in GFR category (3)</li> </ul>
<b>Health-related quality of life (HRQoL)</b>	<p>A combination of a person's physical, mental and social well-being, not merely the absence of disease. A 'utility' is the measure of the preference or value that an individual or society gives a particular health state. It is generally a number between 0 (representing death) and 1 (perfect health). The most widely used measure of benefit in cost-utility analysis is the quality-adjusted life year (QALY), which combines quality of life with length of life. One QALY is equal to one year of life in perfect health. QALYs are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a 0 to 1 scale). It can be measured in terms of the person's ability to carry out the activities of daily life, and freedom from pain and mental disturbance (138).</p>

## APPENDIX 2: TRIAL FLOW DIAGRAM

